

June Industries Ltd.

Formerly known as Kashyap Tele-Medicines Ltd.
Unit # 22 & 23, Hasti Industrial Premises
Co-Op Soc Ltd., Plot No. R-798, Mahape,
MIDC, Ghansoli, Navi Mumbai - 400 701.
Maharashtra, INDIA.
CIN: L46497MH1995PLC085738

M : (+ 91) 89767 92931
E : investors@june4gmp.com
W : www.kashyaptele-medicines.com



16th July 2026

To,
BSE Limited
Ground Floor, P.J. Tower
Dalal Street
Mumbai- 400001

Scrip Code: 531960

Dear Sir/Madam,

**Subject: Submission of Annual Report pursuant to Regulation 34 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to kindly inform you that the 32nd Annual General Meeting of the Company will be held on Monday, 10th August, 2026 at 11:30 A.M. (IST) through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM").

Accordingly, pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of Annual Report for the Financial Year 2025-2026.

The same is also available on the Company's website at the following link:

[Investor Relations - Kashyap Tele-Medicines Limited](#)

Kindly take the same on your record.

Yours faithfully,

For June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)

KALPESH
BIPIN SHETH

Digitally signed by
KALPESH BIPIN SHETH
Date: 2026.07.16
18:06:22 +05'30'

Kalpesh Bipin Sheth
Managing Director (DIN: 00405151)

Encl.: As above

32ND ANNUAL REPORT
2025-2026



June Industries Limited.

(Formerly know as Kashyap Tele-Medicines Limited)

June Industries Limited.

(Formerly know as Kashyap Tele-Medicines Limited)

BOARD OF DIRECTORS

Mr. Kalpesh Bipin Sheth

(DIN: 00405151)

Managing Director

Appointed w.e.f. 23rd May, 2025

Mrs. Heena Kalpesh Sheth

(DIN: 07627681)

Whole-time Director

Appointed w.e.f. 23rd May, 2025

Mr. Amit Agrawal

(DIN: 00169061)

Managing Director

Resigned w.e.f. 24th May, 2025

Mr. Raghav Agrawal

(DIN:02264149)

Non-Executive Non Independent
Director

Resigned w.e.f. 24th May, 2025

Mrs. Amrita Khetan

(DIN:02781781)

Non-Executive Independent Director

(Resigned w.e.f. 14th August, 2025)

Mr. Samir Ambavi

(DIN: 06888550)

Non-Executive Non-Independent
Director

Appointed w.e.f. 23rd May, 2025

Mr. Hardik Bauva

(DIN: 10410954)

Non-Executive Independent Director

Appointed w.e.f. 21st July, 2025

Mr. Hiren Mehta

(DIN: 07139044)

Non-Executive Independent Director

Appointed w.e.f. 21st July, 2025

Mr. Mandar Jain

(DIN: 10883735)

Non-Executive Independent Director

Appointed w.e.f. 21st July, 2025

Mr. Mayank Khetan

(DIN:02412971)

Non-Executive Independent Director

(Resigned w.e.f. 14th August, 2025)

Mr. Devkinandan Sharma

(DIN:07900496)

Non-Executive Independent Director

(Resigned w.e.f. 14th August, 2025)

Mr. Ayushman Khemka

(DIN: 07939582)

Additional Director (Non-Executive Non-
Independent Director)

(resigned w.e.f. 24th May, 2025)

AUDIT COMMITTEE

Mr. Devkinandan Sharma Chairperson

Mr. Hardik Bauva Chairperson*

Mr. Mayank Khetan Member

Mr. Raghav Agrawal Member

Mr. Hiren Mehta Member*

Mr. Mandar Jain Member*

***Reconstituted on July 21, 2025**

STAKEHOLDERS' RELATIONSHIP COMMITTEE

Mr. Devkinandan Sharma Chairperson

Mr. Mandar Jain Chairperson*

Mr. Mayank Khetan Member

Mr. Raghav Agrawal Member

Mr. Kalpesh Bipin Sheth Member*

Mr. Heena Kalpesh Sheth Member*

***Reconstituted on July 21, 2025**

NOMINATION AND REMUNERATION COMMITTEE

Mr. Devkinandan Sharma Chairperson

Mr. Hiren Mehta Chairperson*

Mr. Mayank Khetan Member

Mr. Raghav Agrawal Member

Mr. Mandar Jain Member*

Mr. Hardik Bauva Member*

***Reconstituted on July 21, 2025**

REGISTERED OFFICE

June Industries Limited

(Formerly known as Kashyap

Tele-Medicines Limited)

CIN:

L46497MH1995PLC085738

Unit No.22 & 23, Hasti Industrial Premises CoOp

Soc Ltd, Plot No R-798, Mahape, Mi, Dc, Thane,

Navi Mumbai, Maharashtra, India, 400701.

Email Id: investors@june4gmp.com

Website: www.kashyaptele-medicines.com

CORPORATE OFFICE

Unit No.22 & 23, Hasti Industrial Premises CoOp Soc

Ltd, Plot No R-798, Mahape, Mi, Dc, Thane, Navi

Mumbai, Maharashtra, India, 400701.

Phone No.: +91-89767 92931

Email Id: investors@june4gmp.com

Website: www.kashyaptele-medicines.com

CHIEF FINANCIAL OFFICER**Mr. Raghav Agrawal***Resigned w.e.f. 24th May, 2025***Mr. Anirudh Shah***Appointed w.e.f. 21st July, 2025***COMPANY SECRETARY & COMPLIANCE OFFICER****CS Jyoti Sahu***(Resigned w.e.f. 05th April, 2025)***CS Varsha Sawant***(Appointed w.e.f. 21st July, 2025)***STATUTORY AUDITORS****M/s. Shah Valera & Associates LLP***Chartered Accountants**Mumbai***SECRETARIAL AUDITOR****Rupal Patel***Practicing Company Secretary**Ahmedabad***INTERNAL AUDITORS****M/s. Bhavesh D Shah & Co.,***Chartered Accountants**Mumbai***ISIN : INE108B01029****LISTED AT: BSE Limited (Scrip Code- 531960)****BANKERS : ICICI Bank Limited****REGISTRAR AND SHARE TRANSFER AGENT****MUFG Intime India Private Limited (Link Intime India Private Limited)***Corp. Office: 5th floor, 506 to 508, Amarnath Business Centre - I (ABC - I), Beside Gala Business Centre,**Nr. St. Xavier's College Corner, Off C G Road, Navrangpura, Ahmedabad, Gujarat - 380006. Email Id:**ahmedabad@linkintime.co.in*

CONTENTS		
Sr.No.	Details	Page No.
1	Notice of Annual General Meeting	1-14
2	Board's Report	15-35
	Annexure A - Particulars of Employees	36-38
	Annexure B - Secretarial Audit Report	39-42
	Annexure C - Management Discussion and Analysis Report	43-50
3	MD and CFO Certification on Financial Statement	51
4	Independent Auditor's Report	52-62
5	Balance Sheet	63
6	Statement of Profit and Loss	64
7	Cash Flow Statement	65
8	Changes in Equity	66
9	Notes forming Part of Financial Statements	67-78

NOTICE OF 32ND ANNUAL GENERAL MEETING

Notice is hereby given that the 32nd Annual General Meeting of the Members of **JUNE INDUSTRIES LIMITED (FORMERLY KNOWN AS KASHYAP TELE-MEDICINES LIMITED)** will be held on **Monday, 10th August, 2026 at 11:30 A.M. (IST)** through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM"), to transact the following businesses:

ORDINARY BUSINESS:

1. To consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2026 together with the Board's Report and Report of the Statutory Auditors thereupon:

To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

"RESOLVED THAT the Audited Financial Statements of the Company for the Financial Year ended March 31, 2026 and the Reports of the Board of Directors and Auditor thereon, as circulated to the members, be and are hereby considered and adopted."

2. To appoint a Director in place of Mrs. Heena Kalpesh Sheth (DIN: 07627681), Whole-Time Director, who retires by rotation and, being eligible, offers herself for re-appointment:

To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 152(6) and other applicable provisions of the Companies Act, 2013, Mrs. Heena Kalpesh Sheth (DIN: 07627681), Whole-Time Director, who retires by rotation and being eligible offers herself for re-appointment, be and is hereby re-appointed as a Director (Executive) of the Company, liable to retire by rotation."

For and on behalf of Board of Directors of
June Industries Limited
(Formerly Known as Kashyap Tele-Medicines Limited)

Date : 04th July, 2026

Place : Navi Mumbai

Sd/-
Mr. Kalpesh Bipin Sheth
Managing Director
DIN: 00405151

Registered Office and Corporate Office:

Unit No.22 & 23, Hasti Industrial Premises Co Op Soc Ltd,
Plot No R-798, Mahape, Mi, Dc, Thane, Navi Mumbai, Maharashtra, India, 400701
CIN: L46497MH1995PLC085738
Email Id: investors@june4gmp.com

NOTES:

1. The Ministry of Corporate Affairs ("MCA") has, vide its General Circular No. 3/2025 dated 22nd September 2025, 09/2024 on 19th September 2024, 09/2023 dated 25th September, 2023 read together with circulars dated 28th December, 2022, 05th May, 2022, 08th December, 2021, 14th December, 2021, 13th January, 2021, 05th May, 2020, 13th April, 2020, 08th April, 2020 & any other circulars thereof (hereinafter collectively referred to as "MCA Circulars"), allowed Companies to conduct their Annual General Meeting ("AGM") through VC or OAVM on without the physical presence of the members at a common venue.

In accordance with the Securities and Exchange Board of India circulars dated 3rd October, 2024, 07th October, 2023, 05th January, 2023, 13th May, 2022, 15th January, 2021 and 12th May 2020 (hereinafter collectively referred to as "SEBI Circulars"), the Companies have been provided with the relaxation with requirement under regulation 36(1)(b) and 44(4) of the Listing Regulations for sending physical copies of financial statements (including Board's report, Auditor's report or other documents required to be attached therewith) to the Shareholders for the AGMs conducted till 30th September, 2026.

Accordingly in compliance with applicable provisions of the Companies Act, 2013 read with aforesaid MCA and SEBI Circulars, the 32nd Annual General Meeting ("AGM") of the Company will be held on Monday, 10th August, 2026 at 11:30 A.M. (IST) through VC/OAVM facility to transact the businesses as set out in this Notice and therefore no physical presence of members is required.

2. Relevant Explanatory Statement pursuant to provisions of Section 102 of the Companies Act, 2013 (hereinafter referred to as "the Act") read with Regulations 17 and Regulations 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as "the Listing Regulations"), including any statutory modification(s) or re-enactment(s) thereof for the time being in force, and as required under Secretarial Standard – 2 on General Meetings issued by the Institute of Company Secretaries of India ("ICSI"), is annexed hereto.
3. A brief profile of the Directors proposed to be appointed or re-appointed at this AGM, as set out in this Notice, nature of their expertise in specific functional areas, names of companies in which he/she holds Directorship & Membership/Chairmanship of Board Committee(s), shareholding and relationship between Directors and Key Managerial Personnel as stipulated under Section 152 of the Act, Regulations 26 & 36 of the Listing Regulations and Secretarial Standard – 2 issued by the ICSI, is provided in **Annexure 1** under the Explanatory Statement to this Notice.
4. At the Meeting, Mrs. Heena Kalpesh Sheth (DIN: 07627681) retires by rotation and, being eligible, offers herself for re-appointment. Further the Board of Directors of the Company recommends the re-appointment of Mrs. Heena Kalpesh Sheth.

Mrs. Heena Kalpesh Sheth is not disqualified from continuing as a Director in terms of Section 164 of the Act and has agreed to continue as a Director of the Company. She is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority pursuant to BSE Circular No. LIST/COMP/ 14/2018-19 dated 20th June, 2018.

Pursuant to the Section 152 of the Act, Regulation 36 of the Listing Regulations and Secretarial Standard – 2 issued by the ICSI, the brief profile of the Director and expertise in specific functional areas and other required details pertaining to Director retiring by rotation and eligible for re-appointment under the Ordinary Business Agenda No. 2 of the said Notice is tabled below:

NAME OF DIRECTOR	Mrs. Heena Kalpesh Sheth
Directors Identification Number (DIN)	07627681
Date of Birth & Age	23/10/1970 & 55 years old
Nationality	Indian
Qualification	B.A.
Brief Resume, Experience and Nature of expertise in specific functional areas	Mrs. Heena Kalpesh Sheth, daughter of Mr. Ramesh Chatrabhuj Bhuptani, has over 11 years of professional experience in administration and operational management, particularly within the pharmaceutical and allied sectors.
Date of first Appointment on the Board of the Company	23 rd May, 2025
Shareholding in the Company as on date of this notice	NIL
Directorship held in other Companies as on date of this notice	1) June Enterprises Private Limited
Membership/Chairmanships held in Committees of other Companies as on date of this notice	Nil
Names of the Listed Companies from which resigned/ceased in the past three years	Nil
Relationship with other Directors / Key Managerial Personnel	Spouse of Mr. Kalpesh Bipin Sheh
Number of meetings of the Board of Directors of the Company as attended during the Financial Year 2025-2026	15
Terms & Conditions	As may be mutually decided between Mrs. Heena Kalpesh Sheth and the Board from time to time and shall be liable to retire by rotation pursuant to relevant provisions of the Companies Act, 2013.
Last Remuneration Drawn	Nil
Remuneration proposed to be drawn	She may be paid such amount of sitting fees/remuneration as may be mutually agreed between her and the Board and which shall be within the limits stipulated under the Act

5. The Company has appointed National Securities Depository Limited ("NSDL") for providing e-voting facility including remote e-Voting and participation in the AGM through VC/OAVM facility.
6. Pursuant to aforesaid MCA Circulars, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM and since this AGM is being held through VC/OAVM mode, physical attendance of members has been dispensed with and thus the Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
7. The Board of Directors appointed Mrs. Rupal Patel, Practicing Company Secretary, Ahmedabad as the Scrutinizer to scrutinize the remote e-voting process before the AGM as

well as e-voting process during the AGM fairly and transparently.

8. Pursuant to provisions of Section 112 of the Companies Act, 2013, representatives of the members such as the President of India or the Governor of a State or body corporate can attend the AGM through VC/OAVM and cast their votes through e-voting. Pursuant to provisions of Section 113 of the Companies Act, 2013, Institutional/Corporate members can attend and vote through VC/OAVM by submitting a duly certified copy of the Board Resolution authorizing their representative to attend and vote through e-voting on their behalf to the Scrutinizer by e-mail on their registered Email Id roopalcs2001p@gmail.com or on the Email Id of the Company i.e. investors@june4gmp.com or by uploading the same on "e-Voting" tab in shareholder's login. In case of joint holders attending the AGM, only such joint holder who is higher in the order of names will be entitled to attend & vote.
9. In compliance with the aforesaid MCA Circulars and SEBI Circulars, the 32nd Annual Report along with Notice of the AGM including general guidelines for participation at the AGM through VC/OAVM, procedure for remote e-voting and e-voting during the AGM, shall be sent only by electronic mode to those members whose Email IDs are registered with the Company/Depository/RTA. The same shall also be made available on the website of the Company, i.e. www.kashyaptele-medicines.com, on the website of BSE Limited, i.e. www.bseindia.com and website of NSDL www.evoting.nsdl.com.
10. Members are requested to intimate/update changes, if any, pertaining to their name, postal address, e-mail address, telephone/mobile numbers, Permanent Account Number (PAN), mandate, nominations, power of attorney, bank details such as name of the bank and branch details, bank account number, MICR code, IFSC code, etc.,:
For shares held in electronic form: to their Depository Participants (DPs)
For shares held in physical form: to the Company/Registrar and Transfer Agent in prescribed Form ISR-1 and other forms pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2021/655 dated 3rd November, 2021 and incidental circulars thereof. The above form is available on the website of the Company and the Company has sent letters for furnishing the required details.
11. Members may please note that SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022 and other applicable circulars, has mandated all listed companies to process investors service requests only in dematerialization form of securities viz. Issue of duplicate securities certificate; claim from unclaimed suspense account; renewal/ exchange of securities certificate; endorsement; sub-division/splitting of securities certificate; consolidation of securities certificates/folios; transmission and transposition. Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR-4 or Form ISR-5 in case of transmission, the format of which is available on the Company's website at <https://kashyaptele-medicines.com/investor-relations> and on the website of the Company's Registrar and Transfer Agents. It may be noted that any service request can be processed only after the folio is KYC Compliant. Further, members holding physical shares are urged to dematerialize their holding to avail the various benefits.
12. As per the provisions of Section 72 of the Act and SEBI Circulars, the facility for making nomination is available for the Members in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting Form No. SH-13. If a Member desires to opt out or cancel the earlier nomination and record a fresh nomination, he/she may submit the same in Form ISR-3 or SH-14 as the case may be. The said forms can be downloaded from the Company's website <https://kashyaptele-medicines.com/investor-relations/>. Members are requested to submit the said details to their DP in case the shares are held by them in dematerialized

form and to RTA/Company in case the shares are held in physical form.

13. Pursuant to the provisions of Section 91 of the Act read with Rule 10 of the Companies (Management and Administration) Rules, 2014 and pursuant to Regulation 42 of the Listing Regulations, as amended from time to time, the Register of Members and Share Transfer Books of the Company will be closed from **Tuesday, 04th August, 2026 to Monday, 10th August, 2026** (both days inclusive).
14. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act and all other documents referred to in the notice shall be available for inspection digitally. Members seeking to inspect such documents can send an email to investors@june4gmp.com.
15. In case of any queries in regards to information stated in the Annual Report, the members may write to investors@june4gmp.com in order to get queries resolved.
16. **Instructions to members for voting through electronic means and attending the AGM:**
 - A. Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of the Listing Regulations (as amended), and MCA Circulars, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited ("NSDL") for facilitating voting through electronic means, as the authorized e-voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by NSDL.
 - B. The Members can join the AGM in the VC/OAVM mode 30 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in this Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
 - C. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Act.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING ARE AS UNDER: -

The remote e-voting period begins on Friday, August 07, 2026 at 09:00 A.M. and ends on Sunday, August 09, 2026 at 05:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the **record date (cut-off date) i.e., Monday, August 03, 2026**, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the **cut-off date, being August 03, 2026**.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting for Individual shareholders holding securities in demat mode : In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	- Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS Portal” or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp - Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period. - Shareholders/Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience. NSDL Mobile App is available on  App Store  Google Play 

Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

B) Login Method for e-Voting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
 - a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the ‘initial password’ which was communicated to you. Once you retrieve your ‘initial password’, you need to enter the ‘initial password’ and the system will force you to change your password.
 - c) How to retrieve your ‘initial password’?
 - (i) If your email ID is registered in your demat account or with the company, your ‘initial password’ is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for

- CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
- (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**
6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
 - a) Click on "[Forgot User Details/Password?](#)" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) [Physical User Reset Password?](#) (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
 7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
 8. Now, you will have to click on "Login" button.
 9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically on NSDL e-Voting system.

How to cast your vote electronically on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to csrupalimodi@gmail.com with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "[Forgot User Details/Password?](#)" or "[Physical User Reset Password?](#)" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on : 022 - 4886 7000 or send a request to Ms. Pallavi Mhatre at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to investors@june4gmp.com.
2. In case shares are held in demat mode, please provide DPID-CLID (16 digits DPID + CLID or 16 digits beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to investors@june4gmp.com. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A)** i.e. [Login method for e-Voting for Individual shareholders holding securities in demat mode](#).
3. Alternatively, shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.
 - A. The voting rights of the members shall be in proportion to their shares of the paid-up equity share capital of the company as on the Cut-Off Date of Monday, 03rd August, 2026.
 - B. A Copy of This Notice Has Been/ Shall Be Placed on The Website of The Company and The Website Of NSDL.
 - C. Mrs. Rupal Patel, Practicing Company Secretary has been appointed as the Scrutinizer to scrutinize the voting and remote e-voting process in a fair and transparent manner.
 - D. The Scrutinizer shall, immediately after the conclusion of voting at the general meeting, first count the votes cast at the meeting, thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the company and make not later than two working days of conclusion of the meeting, a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman of the Company or a person authorized by him in writing who shall countersign the same.
 - E. The facility for voting through ballot shall also be made available at the meeting and members attending the meeting who have not already cast their vote by remote e- voting/ ballot shall be able to exercise their voting right at the meeting.
 - F. The members who have casted their votes by remote e-voting prior to the meeting may also attend the meeting but shall not be entitled to cast their vote again.

- G. The Results shall be declared on or after the Annual General Meeting of the Company. The Results declared along with the Scrutinizer's Report shall be placed on the Company's website within 2 (Two) working days of conclusion of the annual general meeting and will be communicated to BSE Limited (BSE), who are required to place them on their website. The same shall also be placed on the website of NSDL.

D. Instructions for Shareholders attending the AGM Through VC/OAVM & E-Voting during Meeting are as under:

- a) The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for e-voting.
- b) The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.
- c) Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM/EGM.
- d) Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
- e) Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
- f) Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
- g) Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least **7 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at investors@june4gmp.com. The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance **7 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at [**investors@june4gmp.com**](mailto:investors@june4gmp.com). These queries will be replied to by the company suitably by email.
- h) Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ ask questions during the meeting.
- i) Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
- j) If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders may be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

Contact Details

Company	: June Industries Limited (Formerly Known as Kashyap Tele- Medicines Limited) CIN: L46497MH1995PLC085738 Regd. Office : Unit No.22 & 23, Hasti Industrial Premises Co Op Soc Ltd, Plot No R-798, Mahape, Mi, Dc, Thane, Navi Mumbai, Maharashtra, India, 400701. E-mail ID: investors@june4gmp.com Website: www.kashyaptele-medicines.com Mobile No.: +91- 8976792931
Registrar and Transfer Agent	: MUFG Intime India Private Limited Corp. Office: 5 th floor, 506 to 508 Amarnath Business Centre - I (ABC - I), Beside Gala Business Centre, Near St. Xavier's College Corner, Off C G Road, Ellisbridge, Ahmedabad, Gujarat, 380 006 Email Id: ahmedabad@in.mpms.mufig.com Website: www.in.mpms.mufig.com Phone No.: 079-26465179
E-Voting Agency	: National Securities Depository Limited Email Id: evoting@nsdl.com
Scrutinizer	: Mrs. Rupal Patel Practicing Company Secretary, Ahmedabad Email Id: roopalcs2001p@gmail.com

For and on behalf of Board of Directors of
June Industries Limited
(Formerly Known as Kashyap Tele-Medicines Limited)

Date : 04th July, 2026
Place : Navi Mumbai

Sd/-
Mr. Kalpesh Bipin Sheth
Managing Director
DIN: 00405151

Registered Office and Corporate Office:
Unit No.22 & 23, Hasti Industrial Premises Co Op Soc Ltd,
Plot No R-798, Mahape, Mi, Dc, Thane, Navi Mumbai, Maharashtra, India, 400701
CIN: L46497MH1995PLC085738
Email Id: investors@june4gmp.com

ANNEXURE 1 TO THE NOTICE

Explanatory Statement pursuant to Section 102 of the Act read with Regulations 17 of Listing Regulations and Secretarial Standard-2 issued by the Institute of Company Secretaries of India

AGENDA NO. 1

In terms of the provisions of Section 129 of the Companies Act, 2013, the Company submits its audited financial statements for F.Y. 2025-26 for adoption by members at the Annual General Meeting ("AGM").

The Board of Directors (the "Board"), on the recommendation of the Audit Committee, has approved audited financial statements for the financial year ended March 31, 2026. Detailed elucidations of the financial statements have been provided under various sections of the Annual Report, including the Board's Report and Management Discussion and Analysis Report.

The Audited Financial Statements of the Company along with the reports of the Board of Directors and Auditors thereon:

- have been sent to the members at their registered e-mail address; and
- have been uploaded on the website of the Company i.e., www.kashyaptele-medicines.com under the "Investors" section.

M/s. SHAH VALERA & ASSOCIATES LLP (FRN.- W100238), Statutory Auditors has issued an unmodified audit report on the financial statements and has confirmed that the financial statements, represent a true and fair view of the state of affairs of the Company

None of the Directors or Key Managerial Personnel of the Company including their relatives, except to the extent of their respective shareholdings in the Company, in any way, financially or otherwise, is interested or concerned in this resolution.

The Board recommends the Ordinary Resolution set out at Item No. 1 for approval of the members of the Company

The Board recommends resolution at Item No. 1 relating to adoption of Financial Statements of the Company, for approval of the members as an Ordinary Resolution.

AGENDA NO. 2

Section 152 of the Companies Act, 2013 ("Act") mandate certain number of directors to retire at every Annual General Meeting ("AGM") of the Company who can offer themselves for re-appointment. In compliance with this requirement, Mrs. Heena Kalpesh Sheth (DIN: 07627681), Director, retires by rotation at the ensuing AGM. She is eligible and has offered herself for re-appointment.

A brief profile of Mrs. Heena Kalpesh Sheth (DIN: 07627681) to be reappointed as Director is given under the heading "Details of Directors proposed to be appointed and re-appointed, pursuant to Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Secretarial Standard-2 on General Meetings issued by the Institute of Company Secretaries of India" elsewhere in the Notice.

The Company has received declaration from Mrs. Heena Kalpesh Sheth that she is not disqualified from being appointed as Director in terms of Section 164 of the Act.

Mrs. Heena Kalpesh Sheth has contributed immensely to the Company's growth. She has the vast experience in the field of Management & Finance.

Except the above, none of other Directors or Key Managerial Personnel of the Company including their relatives,
32nd Annual Report 2025-2026 **Notice**

ANNEXURE 1 TO THE NOTICE

except to the extent of their respective shareholdings in the Company, in any way, financially or otherwise, is interested or concerned in this resolution.

The Board recommends resolution at Item No. 2 relating to re-appointment of Mrs. Heena Kalpesh Sheth as Director, for approval of the members as an Ordinary Resolution.

**For and on behalf of Board of Directors of
June Industries Limited
(Formerly Known as Kashyap Tele-Medicines Limited)**

**Date : 04th July, 2026
Place : Navi Mumbai**

**Sd/-
Mr. Kalpesh Bipin Sheth
Managing Director
DIN: 00405151**

Registered Office and Corporate Office:

Unit No.22 & 23, Hasti Industrial Premises Co Op Soc Ltd,
Plot No R-798, Mahape, Mi, Dc, Thane, Navi Mumbai, Maharashtra, India, 400701
CIN: L46497MH1995PLC085738
Email Id: investors@june4gmp.com

BOARD'S REPORT
FINANCIAL YEAR 2025-2026

Dear Members,

Your Directors with immense pleasure presenting a 32nd Board's Report on the business and operations of the Company together with the Audited Financial Statements and the Auditors' Report thereon for the Financial Year ended on 31st March, 2026.

1. FINANCIAL HIGHLIGHTS:

A summary of your Company's financial results for the Financial Year 2025-2026 is as under:

(Rs. in Lakhs except EPS)

Particulars	2025-2026	2024-2025
Revenue from Operations	19.70	19.20
Other Income	1.88	0.00
Total Income	21.58	19.20
Expenditure		
Employee benefits expense	1.91	10.81
Other Expenses	65.73	8.40
Total Expenses	67.64	19.21
Profit/(Loss) Before Exceptional items and Tax	(46.06)	(0.01)
Exceptional Items	-	-
Profit before Tax	(46.06)	(0.01)
Tax Expenses		
Current Tax	-	-
Tax relating to P.Y.	-	0.02
Income tax expenses	-	0.02
Net Profit/ (Loss) for the period	(46.06)	(0.03)
Earning per Equity Share @ Face Value of Rs. 1/- each (Basic & Diluted)	(0.000)	(0.000)

2. HIGHLIGHTS OF PERFORMANCE:

Total Income: The total income increased by 12.40 % to Rs.21.58 Lakhs in comparison to Rs.19.20 Lakhs of Previous Financial Year 2024-2025.

EBIDTA: The EBIDTA of your Company stood at Rs.(46.06) Lakhs in comparison to Rs.(0.01) Lakhs of Previous Financial Year 2024-2025.

PAT: The Company had loss of Rs.(46.06) Lakhs in comparison to loss of Rs. (0.03) Lakhs of Previous Financial Year 2024-2025.

3. DIVIDEND:

Your Directors have not recommended any dividend for the Financial Year 2025-2026 in view of loss occurred by the Company. Further the Dividend Distribution Policy as per Regulation 43A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (hereinafter referred to as "Listing Regulations") is not applicable to the Company as it does not fall under top 1000 Listed Companies based on its market capitalization as at the Financial Year ended on 31st March, 2026.

4. FINANCE:

The Company has not borrowed loan from any Bank during the year under review.

5. DETAILS PERTAINING TO SHARES IN SUSPENSE ACCOUNT:

The Company does not have any shares in the demat suspense account or unclaimed suspense account. Hence, Disclosures with respect to demat suspense account/ unclaimed suspense account are not required to mention here..

6. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF):

The Company has not declared any dividend in past years, hence there are no amounts lying and liable for transfer to Investor Education and Protection Fund.

7. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT:

The Business Responsibility and Sustainability Report as per Regulation 34(2)(f) of the Listing Regulations, is not applicable to the Company as it does not fall under top 1000 Listed Companies on the basis of market capitalization as at the Financial Year ended on 31st March, 2026.

8. INDIAN ACCOUNTING STANDARDS (IND AS):

The Company has adopted Indian Accounting Standards ('Ind-AS') prescribed under Section 133 of the Companies Act, 2013 (hereinafter referred to as "the Act") from 1st April, 2017 and accordingly the financial statements for the reporting period and all the periods presented have been prepared in accordance with Indian Accounting Standards notified under Section 133, read with relevant rules issued thereunder and the other accounting principles generally accepted in India. Further, all the applicable amendments stated in the Schedule III of the Companies Act, 2013 have also been adopted and presented in the Financial Statements for the reporting period.

9. AUDIT TRAIL APPLICABILITY (AUDIT AND AUDITORS) RULES 2014 - RULE 11 OF THE COMPANIES ACT 2013:

The Company has used accounting software for maintaining its books of account for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the softwares.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is applicable for the financial year ended 31st March, 2026.

10. APPOINTMENT OF DESIGNATED PERSON (MANAGEMENT AND ADMINISTRATION) RULES 2014 - RULE 9 OF THE COMPANIES ACT 2013:

In accordance with Rule 9 of the Appointment of Designated Person (Management and Administration) Rules 2014, it is essential for the company to designate a responsible individual for ensuring compliance with statutory obligations.

The company has proposed and appointed Mr. Kalpesh Bipin Sheth (DIN: 00405151) a Designated person in a Board meeting and the same has been reported in Annual Return of the company.

11. DECLARATION BY INDEPENDENT DIRECTOR & BY THE COMPANY:

All Independent Directors have given declarations that they meet the criteria of independence as laid down under Section 149(6) of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

12. SHARE CAPITAL:

a) Authorized Share Capital

There was no change in the Authorised Capital of the Company during the Financial Year 2025-2026. The Authorized Share Capital of the Company as at 31st March, 2026 stood at Rs. 15,00,00,000/-.

b) Issued Share Capital

The Issued Share Capital of the Company as at 31st March, 2026 stood at Rs. 5,00,00,000/-.

During the year under review, the Company has not issued shares with differential voting rights nor has granted any stock options or sweat equity. As on 31st March, 2026, none of the Directors of the Company hold any instruments convertible into equity shares of the Company.

c) Subscribed and Paid up Share Capital

The Subscribed and Paid up Share Capital of the Company as at 31st March, 2026 stood at Rs. 4,77,22,000/-.

13. CIRCULATION OF ANNUAL REPORT IN ELECTRONIC FORM:

Pursuant to the exemptions provided by the Securities and Exchange Board of India and Ministry of Corporate Affairs as mentioned in the notice to AGM, the Annual Report for the Financial Year 2025-2026 will be sent to members through electronic mode (via e-mail) only, on the email id registered with the Registrar and Share Transfer Agent of the Company. Members are requested to register/ update their respective email ids for receiving further electronic communications.

14. TRANSFER TO RESERVES:

The Company has not transferred any amount to the General Reserve for the Financial Year ended on 31st March, 2026. However, the balance of Shares Forfeiture Account of Rs. 11,97,500/- against application money of 22,78,000 equity shares as forfeited by the Company earlier has been transferred to Capital Reserve Account in the Financial Year 2018-2019, in accordance with the applicable accounting provisions.

15. INFORMATION ABOUT SUBSIDIARY/ JOINT VENTURE /ASSOCIATE COMPANY:

During the year under review, there were no Associate/Subsidiary/Joint Venture of the Company. However, the Company became a subsidiary of June Enterprises Private Limited upon acquisition of 60.88% in Share Capital. (June Enterprises Private Limited has acquired 1,21,81,118 (25.53%) out of actual open offer of 1,24,07,720 equity shares constituting 26%. This Offer is triggered in compliance with the provisions of Regulations 3(1), and 4 of the SEBI (SAST) Regulations, pursuant to the execution of the Share Purchase Agreement dated Wednesday, March 05, 2025, wherein the Acquirer has agreed to acquire 1,68,72,900 Sale Shares, representing 35.35% of the Voting Share Capital of the Target Company from the Selling Promoter Shareholders, namely being, Mr. Jitendra Tarachand Agrawal (Selling Promoter Shareholder 1), Mr. Amit Yamunadutt Agarwal (Selling Promoter Shareholder 2), Mr. Radheshyam Tarachand Agrawal (Selling Promoter Shareholder 3), Ms. Yamunadutt Amilal Agrawal (Selling Promoter Shareholder 4), and M/s. Jindal Worldwide Ltd (Selling Promoter Shareholder 5) at a negotiated price of ₹1.50/- per Sale Share, aggregating to an amount of ₹2,53,09,350.00/-, payable subject to the terms and conditions specified in the said Share Purchase Agreement. Post Open offer June Enterprises Private Limited hold 2,90,54,018 equity shares constituting 60.88% under promoter category in June Enterprise Limited. And accordingly, June Enterprise Limited become subsidiary company in accordance with section 2(87) of the companies act, 2013, hence AOC-1 is not applicable to the Company.

16. ANNUAL RETURN:

Pursuant to provisions of Section 92(3) read with Section 134(3)(a) of the Act, the Annual Return in Form MGT-7 as on 31st March, 2026 is available on the Company's website at <https://kashyaptele-medicines.com/investor-relations/>.

17. DISCLOSURE RELATING TO REMUNERATION OF DIRECTORS, KEY MANAGERIAL PERSONNEL AND PARTICULARS OF EMPLOYEES:

The details of remuneration of Directors, Key Managerial Personnel and Particulars of Employees and other information required under Section 197(12) of the Act read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is set out in “Annexure – A” which forms part of this Board’s Report.

Further during Financial Year 2025-2026, no employee has received remuneration in excess of the limits set out in rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (as amended).

18. MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT:

There are no material changes and commitments, affecting the financial position of the Company which has occurred between the end of financial year as on 31st March, 2026 and the date of Director’s Report.

19. CHANGE IN THE NATURE OF BUSINESS:

There has been changes in the nature of business of the Company from current business to trading of pharmaceutical products, hygiene products and healthcare products, during the year under review, which was approved by the shareholders vide postal ballot notice dated 14th August, 2025, to avail the opportunity present in market.

20. CHANGE OF NAME:

The Company has changed its name from Kashyap Tele-Medicines Limited to June Industries Limited, which was approved by the shareholders vide postal ballot notice dated 14th August, 2025.

21. BOARD OF DIRECTORS, COMPOSITION AND INDEPENDENCE:

The Company recognizes the importance of a diverse Board. The Board is entrusted with the ultimate responsibility of the management, direction and performance of the Company and has been vested with the requisite powers, authorities and duties. The composition of Board is in line with the applicable provisions of the Act and the Listing Regulations.

As on 31st March, 2026, the Board comprises of Two Executive Directors, One Non-Executive Non-Independent Directors and three Independent Directors.

Further, pursuant to provisions of Section 164 of the Act, all the Directors of the Company had confirmed that they are not disqualified from being appointed as Directors.

Further, the Company has received necessary declarations from each of the Independent Director that they continue to meet the criteria of independence as laid down under Sections 149(6) & (7) of the Act and Regulations 16(1)(b) & 25 of the Listing Regulations and that they are not debarred from holding the office of director by virtue of any SEBI order or any other such authority. All the Independent Directors have confirmed that they are in compliance with Rules 6(1) and 6(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014.

Further, Mrs. Heena Kalpesh Sheth (DIN: 07627681), Whole-Time Director of the Company retires by rotation at the ensuing AGM and being eligible, offered herself for re-appointment. Her brief resume, nature of expertise, details of directorships held in other companies & other details is appended as an Annexure to the Notice of this AGM.

During the year following changes were occurred in the Board of Directors of the Company:

- 1) Mr. Kalpesh Bipin Sheth (DIN: 00405151) appointed as Managing Director of the Company w.e.f. 23rd May, 2025 for the period of five consecutive years,

- 2) Mrs. Heena Kalpesh Sheth (DIN: 07627681) appointed as Whole-Time Director of the Company w.e.f. 23rd May, 2025 for the period of five consecutive years,
- 3) Mr. Samir Ambavi (DIN: 06888550) appointed as Additional Director in the category of Non-Executive and Non-Independent Director of the Company w.e.f. 23rd May, 2025, and was regularized in the Annual General Meeting held on 24th September, 2025,
- 4) Accepted Resignation of Mr. Amit Agrawal (DIN-00169061) from the post of Managing Director of the Company effective from the close of the business hours on 24th May, 2025 due to pre-occupation,
- 5) Accepted Resignation of Mr. Raghav Agrawal (DIN-02264149) from the post of Director of the Company effective from the close of the business hours on 24th May, 2025 due to pre-occupation,
- 6) Accepted Resignation of Mr. Raghav Agrawal (DIN-02264149) from the post of Chief Financial Officer of the Company effective from the close of the business hours on 24th May, 2025 due to pre-occupation,
- 7) Accepted Resignation of Mr. Ayushman Khemka (DIN-07939582) from the post of Director of the Company effective from the close of the business hours on 24th May, 2025 due to pre-occupation,
- 8) Mr. Hardik Bauva (DIN: 10410954) appointed as Additional Director in the category of Non-Executive and Independent Director of the Company w.e.f. 21st July, 2025, and was regularized in the Annual General Meeting held on 24th September, 2025,
- 9) Mr. Hiren Mehta (DIN: 07139044) appointed as Additional Director in the category of Non-Executive and Independent Director of the Company w.e.f. 21st July, 2025, and was regularized in the Annual General Meeting held on 24th September, 2025,
- 10) Mr. Mandar Jain (DIN: 10883735) appointed as Additional Director in the category of Non-Executive and Independent Director of the Company w.e.f. 21st July, 2025, and was regularized in the Annual General Meeting held on 24th September, 2025,

22. MEETINGS OF THE BOARD:

Sixteen Meetings of the **Board** of Directors of the Company were convened and held during the Financial Year 2025-2026 on 05th April, 2025, 23rd May, 2025, 09th June, 2025, 21st July, 2025, 24th July, 2025, 07th August, 2025, 14th August, 2025, 18th August, 2025, 25th August, 2025, 02nd October, 2025, 04th October, 2025, 07th November, 2025, 12th November, 2025, 10th February, 2026, 20th February, 2026 and 23rd March, 2026. The maximum gap between two Board Meetings does not exceed one hundred and twenty days. The composition of the Board as well as the particulars of attendance at the Board meetings are given below:

Name of Director	Category	Attendance of Meeting of Board of Directors held on															Attendance at the AGM held on 24 th Sept emb
		05 th April, 2025	23 rd May, 2025	09 th June, 2025	21 st July, 2025	24 th July, 2025	07 th August, 2025	14 th August, 2025	18 th August, 2025	25 th August, 2025	02 nd October, 2025	04 th October, 2025	7 th November, 2025	12 th November, 2025	10 th February, 2026	20 th February, 2026	

																			er, 202 5
Mr. Amit Agrawal *	Managi ng Director	✓	✓	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Mrs. Amrita Khetan **	Non-Exec utive Non Inde pend ent Direc tor	✓	✓	✓	✓	✓	X	X	X	X	X	X	X	X	X	X	X	X	X
Mr. Raghav Agrawal *	Non-Exec utive Non Inde pend ent Direc tor	✓	✓	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Mr. Devkin andan Sharma **	Indepe ndent Direct or	✓	✓	✓	✓	✓	✓	✓	X	X	X	X	X	X	X	X	X	X	X
Mr. Mayank Khetan **	Indepe ndent Direct or	✓	✓	✓	✓	✓	✓	✓	X	X	X	X	X	X	X	X	X	X	X
Mr. Ayushman Khemka *	Non-Executi ve Non Indepe ndent Direct or	✓	✓	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Mr. Kalpesh Bipin Sheth^	Manag ing Direct or	X	X	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Mrs. Heena Kalpesh Sheth^	Whole -time Direct or	X	X	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

Mr. Samir Ambavi [^]	Non-Executive Non Independent Director	X	X	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Mr. Hardik Bauva [^]	Independent Director	X	X	X	X	X	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Mr. Hiren Mehta [^]	Independent Director	X	X	X	X	X	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Mr. Mandar Jain ^{^^}	Independent Director	X	X	X	X	X	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
✓ Present																			
X Leave of Absence																			

Note:

[^] appointed w.e.f. 23rd May, 2025.

* Resigned w.e.f. 24th May, 2025.

^{^^}appointed w.e.f. 21st July, 2025.

** Resigned w.e.f. 14th August, 2025.

23. KEY MANAGERIAL PERSONNEL (KMP):

The following personnel functioned as Key Managerial Personnel pursuant to the provisions of Sections 2(51) and 203 of the Act read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (as amended from time to time):

- Mr. Amit Agrawal: Managing Director; (Resigned with effect from 24th May, 2025)
- Mr. Kalpesh Bipin Sheth: Managing Director (Appointed on 23rd May, 2025)
- Mr. Raghav Agrawal: Chief Financial Officer; (Resigned with effect from 24th May, 2025)
- Mr. Anirudh Shah: Chief Financial Officer; (Appointed on 21st July, 2025)
- Ms. Jyoti Sahu: Company Secretary & Compliance Officer (Resigned with effect from 05th April, 2025)
- Ms. Varsha Ninad Sawant: Company Secretary & Compliance Officer (Appointed on 21st July, 2025)

24. DIRECTORS' RESPONSIBILITY STATEMENT:

In terms of Section 134(3)(c) of the Act in relation to financial statements of the Company for the

Financial Year ended on 31st March, 2026, the Board of Directors states that:

- (a) in the preparation of the annual accounts, the applicable accounting standards read with requirements set out under Schedule III to the Act, have been followed and there are no material departures from the same;
- (b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2026 and of the profit and loss of the Company for the Financial Year ended 31st March, 2026;
- (c) the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) the annual accounts / financial statements have been prepared on a 'going concern' basis;
- (e) proper internal financial controls are in place and are adequate and operating effectively;
- (f) the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

25. POLICY ON DIRECTORS' APPOINTMENT, REMUNERATION AND DISCHARGE OF THEIR DUTIES:

Pursuant to provisions of Section 178(3) of the Act, the Company has adopted a Nomination & Remuneration Policy for the Directors, Key Managerial Personnel and other employees. The broad parameters covered under the Policy are - Company Philosophy, Guiding Principles, Nomination of Directors & KMPs, Remuneration of Directors and other Employees. The policy is based on the commitment of fostering a culture of leadership with trust.

Pursuant to provisions of Section 134(3) of the Act, the Nomination, Remuneration and Succession policy of the Company is available on the Company's website at <https://kashyaptele-medicines.com/wp-content/uploads/2024/05/3.-Nomination-Remuneration-Succession-Policy.pdf>. It is affirmed that the remuneration paid to Directors, Key Managerial Personnel and all other employees is as per the Policy formulated by the Company.

26. COMMITTEES OF THE BOARD:

The Company's Board has the following three Committees as on 31st March, 2026:

- I. Audit Committee;
- II. Stakeholders Relationship Committee; and
- III. Nomination & Remuneration Committee.

I. AUDIT COMMITTEE

The Company has constituted Audit Committee pursuant to provisions of Regulation 18 of the Listing Regulations and Section 177 of the Act. The Audit Committee has been given powers, role and terms of reference as envisaged under Regulation 18 of the Listing Regulations and Section 177 of the Act and besides that other terms as referred by the Board of Directors from time to time.

Five meetings of the Audit Committee were convened and held during the Financial Year 2025-2026 on 23rd May, 2025, 07th August, 2025, 14th August, 2025, 12th November, 2025 and 10th February, 2026. The maximum gap between two Audit Committee meetings does not exceed one hundred and twenty days. The composition of the Committee was reconstituted on 21st July, 2025, after that new composition as well as the particulars of attendance at the Committee meetings are given below:

Name of Members	Designation	Category	Attendance at the Audit Committee Meetings held on				
			23 rd May, 2025	07 th August, 2025	14 th August, 2025	12 th November, 2025	10 th February, 2026
Mr. Devkinandan Sharma	Chairperson	Independent Director	✓	X	X	X	X
Mr. Mayank Khetan	Member	Independent Director	✓	X	X	X	X
Mr. Raghav Agrawal	Member	Non-Executive Non-Independent Director	✓	X	X	X	X
Mr. Hardik Bauva	Chairperson	Independent Director	X	✓	✓	✓	✓
Mr. Hiren Mehta	Member	Independent Director	X	✓	✓	✓	✓
Mr. Mandar Jain	Member	Independent Director	X	✓	✓	✓	✓
✓	Present						
x	Leave of Absence						

TERMS OF REFERENCE OF AUDIT COMMITTEE:

- Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- Recommending the appointment, remuneration and terms of appointment of auditors of the Company;
- Approval of payment to Statutory Auditors for any other services rendered by the Statutory Auditors;
- Reviewing, with the management, the Annual Financial Statements and Auditor's Report thereon before submission to the Board for approval, with particular reference to:
 - Matters required to be included in the Director's Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-Section 3 of Section 134 of the Act.
 - Changes, if any, in accounting policies, practices and reasons for the same.
 - Major accounting entries involving estimates based on the exercise of judgment by management.
 - Significant adjustments made in the financial statements arising out of audit findings.
 - Compliance with the Listing Regulations and other legal requirements relating to financial statements.
 - Disclosure of any related party transactions.
 - Modified opinion(s) in the draft audit report.
- Reviewing, with management, the quarterly financial statements before submission to the Board for approval;
- Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for

- purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency, monitoring the utilization of proceeds of a public or rights issue or preferential issue or qualified institutions placement, and making appropriate recommendations to the Board to take up steps in this matter;
- g) Review and monitor the auditor's independence and performance and effectiveness of audit process;
 - h) Approval or any subsequent modification of transactions of the Company with related parties;
 - i) Scrutiny of inter-corporate loans and investments;
 - j) Valuation of undertakings or assets of the Company, wherever it is necessary;
 - k) Evaluation of internal financial controls and risk management systems;
 - l) Reviewing, with the management, performance of Statutory and Internal Auditors, adequacy of Internal Control Systems;
 - m) Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;
 - n) Discussion with Internal Auditors of any significant findings and follow up there on;
 - o) Reviewing the findings of any internal investigations by the Internal Auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board;
 - p) Discussion with Statutory Auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
 - q) To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;
 - r) To review the functioning of the Whistle Blower Mechanism;
 - s) Approval of appointment of chief financial officer (i.e., the Whole-Time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience and background, etc. of the candidate;
 - t) Reviewing the Management letters/ letters of Internal Control weaknesses issued by Statutory Auditor;
 - u) Carrying out any other function as is mentioned in the terms of reference of the Audit Committee;
 - v) Review of Management discussion and analysis of financial condition and results of operations;
 - w) Review of Statement of significant related party transactions (as defined by the Audit Committee), submitted by management;
 - x) Review of Internal audit reports relating to internal control weaknesses;
 - y) Review of appointment, removal and terms of remuneration of the Chief Internal Auditor;
 - z) Reviewing the utilization of loans and / or advances from / investment by the holding Company in the subsidiary exceeding rupees 100 Crores or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments;

- aa) Consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders, if any;
- bb) Review of statement of deviations:
 - i. Quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1) of the Listing Regulations;
 - ii. Annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/ notice in terms of Regulation 32(7) of the Listing Regulations;
- cc) Carrying out any other function as may be required in pursuance of the decision of the Board of Directors of the Company or any provision under the Act or Listing Regulations or any other applicable law.

II. STAKEHOLDERS' RELATIONSHIP COMMITTEE

The Company has constituted Stakeholders' Relationship Committee pursuant to provisions of Regulation 20 of the Listing Regulations and Section 178 of the Act. The Stakeholders' Relationship Committee has been given powers, role and terms of reference as envisaged Regulation 20 of the Listing Regulations and Section 178 of the Act and besides that other terms as referred by the Board of Directors from time to time.

Four Meetings of the Stakeholders' Relationship Committee were convened and held during the Financial Year 2025- 2026 on 07th April, 2025, 18th July, 2025, 28th October, 2025 and 28th January, 2026. The composition of the Committee was reconstituted on 21st July, 2025, after that new composition as well as the particulars of attendance at the Committee meetings are given below:

Name of Members	Designation	Caterogy	Attendance at the Stakeholders' Relationship Committee Meetings Held on			
			07 th April, 2025	18 th July, 2025	28 th October, 2025	28 th January, 2026
Mr. Raghav Agrawal	Chairperson	Non-Executive Non-Independent Director	✓	X	X	X
Mr. Amit Agrawal	Member	Managing Director	✓	X	X	X
Mr. Mayank Khetan	Member	Independent Director	✓	✓	X	X
Mr. Samir Ambavi	Chairperson	Non-Executive Non Independent Director	X	✓	X	X
Mr. Mandar Jain	Chairperson	Independent Director	X	X	✓	✓
Mr. Kalpesh Bipin Sheth	Member	Managing Director	X	✓	✓	✓
Mr. Heena Kalpesh Sheth	Member	Whole-Time Director	X	X	✓	✓
✓	Present					
x	Leave of Absence					

TERMS OF REFERENCE OF STAKEHOLDERS' RELATIONSHIP COMMITTEE:

The Stakeholders' Relationship Committee of the Company is, inter alia, entrusted with the below roles and responsibilities:

- a) To attend requests from the members for transfer / transmission of shares and all matters incidental or related thereto; investigate complaints relating to allotment of shares, approval of transfer or transmission of shares or any other securities and resolving the grievances of the security holders of the listed entity including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc.;
- b) To attend matters relating to dematerialization / re-materialization of shares / other securities and all matters incidental or related thereto;
- c) To advise the Board on matters incidental or relating to issue of Bonus Shares & Rights Shares, etc.;
- d) To attend issues of duplicate certificates and new certificates on split / consolidation / renewal;
- e) To review measures taken for effective exercise of voting rights by shareholders;
- f) To attend matters relating to compliance with the Listing Regulations and other statutory requirements concerning the interests of holders of shares and other securities;
- g) Review adherence to the service standards adopted by the listed entity in respect of various services being rendered by the Registrar & Share Transfer Agent;
- h) Review various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the Company;
- i) Other allied matter(s) out of and incidental to these functions and not included herein above;
- j) To carry out such other function as may be required pursuant to the decision of the Board of Directors of the Company and other provisions of the Act or Listing Regulations or any other applicable law.

The status of shareholders' complaints received so far/number not solved to the satisfaction of shareholders/number of pending share transfer transactions (as on March 31, 2026 is given below): -

Complaints Status: 01.04.2025 to 31.03.2026	
Number of complaints received so far	0
Number of complaints solved	0
Number of pending complaints	0

Compliance Officer:

Ms. Varsha Sawant is Compliance Officer of the company for the purpose of complying with various provisions of Securities and Exchange Board of India (SEBI), Listing Agreement with Stock Exchanges, Registrar of Companies and for monitoring the share transfer process etc.

Dematerialization of shares and liquidity:

Details of Registrar and Share Transfer agent of the Company for dematerialization of shares:

Name: M/s. MUFG Intime India Pvt. Ltd

Address: 5th Floor, 506 to 508 Amarnath Business Centre - I (ABC - I), Beside Gala Business Centre, Nr. St. Xaviers College Corner, Off C G Road, Navarangpura ,Ahmedabad,Gujarat,380009.

Tel: + 079 - 26465179

Email: ahmedabad@in.mpms.mufg.com

III. NOMINATION AND REMUNERATION COMMITTEE AND POLICY THEREON

The Company has constituted Nomination and Remuneration Committee pursuant to provisions of Regulation 19 of the Listing Regulations and Section 178 of the Act. The Nomination and Remuneration Committee has been given powers, role and terms of reference as envisaged under Regulation 19 of the Listing Regulations and Section 178 of the Act and besides that other terms as referred by the Board of Directors from time to time.

Five Meetings of the Nomination and Remuneration Committee were convened and held during the Financial Year 2025-2026 on 23rd May, 2025, 21st July, 2025, 07th August, 2025, 18th August, 2025 and 25th August, 2025. The composition of the Committee was reconstituted on 21st July, 2025, after that new composition as well as the particulars of attendance at the Committee meetings are given below:

Name of Members	Designation	Caterogy	Attendance at the Nomination and Remuneration Committee Meeting held on				
			23 rd May, 2025	21 st July, 2025	07 th August, 2025	18 th August, 2025	25 th August, 2025
Mr. Devkinandan Sharma	Chairperson	Independent Director	✓	✓	X	X	X
Mr. Mayank Khetan	Member	Independent Director	✓	✓	X	X	X
Mr. Raghav Agrawal	Member	Non-Executive Non-Independent Director	✓	✓	X	X	X
Mr. Samir Ambavi	Member	Non-Executive Non-Independent Director		✓	X	X	X
Mr. Hiren Mehta	Chairperson	Independent Director	X	X	✓	✓	✓
Mr. Mandar Jain	Member	Independent Director	X	X	✓	✓	✓
Mr. Hardik Bauva	Member	Independent Director	X	X	✓	✓	✓
✓ Present							
x Leave of Absence							

TERMS OF REFERENCE OF NOMINATION AND REMUNERATION COMMITTEE:

- Formulating the criteria for determining qualifications, positive attributes and independence of a director and recommending to the Board a policy, relating to the remuneration of the directors, key managerial personnel and other employees;

- b. For every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:
 - use the services of an external agencies, if required;
 - consider candidates from a wide range of backgrounds, having due regard to diversity; and
 - consider the time commitments of the candidates.
- c. Formulating of criteria for evaluation of performance of the independent directors and the Board;
- d. Devising a policy on Board diversity;
- e. Identifying persons who qualify to become directors and who may be appointed in senior management in accordance with the criteria laid down, recommending to the Board their appointment and removal;
- f. Determining whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors;
- g. Recommend to the board, all remuneration, in whatever form, payable to senior management;
- h. Analyzing, monitoring and reviewing various human resource and compensation matters;
- i. Determining the Company's policy on specific remuneration packages for executive directors including pension rights and any compensation payment, and determining remuneration packages of such directors; and
- j. To carry out any other function as may be required in pursuance of the decision of the Board of Directors of the Company or any provision under the Act or the Listing Regulations or any other applicable law.

PERFORMANCE EVALUATION OF INDEPENDENT DIRECTORS:

The evaluation process is designed to enhance the overall effectiveness of the Board of Directors and its Committees. During the year under review, the Committee carried out evaluation of performance of every Director, KMP and Senior Management Personnel.

POLICIES

The Board of Directors upon recommendation of Nomination and Remuneration Committee, has developed Nomination, Remuneration & Succession Policy, which inter alia, includes the following functions:

1. Appointment of Directors and Senior Management and succession planning for orderly succession to the Board and the Senior Management.
2. Remuneration of the Directors, Key Managerial Personnel and other senior level employees.

Nomination, Remuneration & Succession Policy is placed on the Company's website at <https://kashyaptele-medicines.com/wp-content/uploads/2024/06/Nomination-Remuneration-Succession-Policy.pdf>

REMUNERATION OF DIRECTORS

Below are the details of remuneration to Directors of the Company for the Financial Year 2025-2026:

Name of Directors	Remuneration (J in Lakhs)
Mr. Amit Agrawal	Nil
Mr. Raghav Agrawal	1.20
Mrs. Amrita Khetan	Nil
Mr. Devkinandan Sharma	Nil
Ms. Surabhi Agrawal	Nil
Mr. Mayank Khetan	Nil
Mr. Ayushman Khemka	Nil
Mr. Kalpesh Bipin Sheth	Nil
Mrs. Heena Kalpesh Sheth	Nil
Mr. Samir Ambavi	Nil
Mr. Hardik Bauva	Nil
Mr. Hiren Mehta	Nil
Mr. Mandar Jain	Nil

During the year under review, there were no pecuniary relationships or transactions between the Company and any of its Non-Executive and Independent Directors other than those disclosed above. Further, the Company has not granted stock options to Non-Executive and Independent Directors.

Upon approval by the Board and the Shareholders at the general meeting, and subject to requisite regulatory approvals as may be necessary, executive and non-executive Directors have received remuneration determined through mutual agreement with the Company. Additionally, the remuneration paid to Directors, senior management and other employees is in accordance with their terms of appointment and the Company's Nomination Remuneration and Succession Policy.

27. SEPARATE MEETING OF INDEPENDENT DIRECTORS:

Schedule IV of the Act, Listing Regulations and Secretarial Standard – 1 on Meetings of the Board of Directors mandates that the Independent Directors of the Company hold at least one meeting in a year, without the attendance of Non-Independent Directors.

The Independent Directors Meeting was held on March 16, 2026. The Independent Directors, inter alia, discussed and reviewed performance of Non-Independent Directors, the Board as a whole, Chairperson of the Company and assessed the quality, quantity and timeliness of flow of information between the Company's management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

In addition to formal meetings, frequent interactions outside the Board Meetings also take place between the Independent Directors and with the Chairperson, and rest of the Board.

28. REPORT ON RISK MANAGEMENT POLICY:

Pursuant to Section 134(3)(n) of the Act and Regulation 17(9) of the Listing Regulations, the Company has laid down a Risk Management Policy to identify threat of such events which if occur will adversely affect ability of Company to achieve objectives, ability to implement business strategies, the manner in which the Company operates and has reputation as "Risks". A detailed exercise is carried out to

identify, evaluate, manage and monitoring all types of risks. Further, the Constitution of Risk Management Committee is not applicable to the Company.

29. LIQUIDITY:

Your Company maintains sufficient cash to meet our strategic objectives. We clearly understand that the liquidity in the Balance Sheet is to ensure balance between earning adequate returns and the need to cover financial and business risks. Liquidity also enables your Company to position itself for quick responses to market dynamics.

30. EVALUATION OF THE BOARD AND ITS COMMITTEES:

The Board has carried out the annual performance evaluation of effectiveness of its performance, the directors individually as well as the evaluation of the working of its various committees pursuant to the provisions of Section 134(3)(p) and 178(2) of the Act and Regulation 19 & 34 read with Part D of Schedule II of the Listing Regulations. An indicative list of factors on which evaluation of the individual Directors, the Board and the Committees was carried out includes profile, experience, contribution of each Director to the growth of the Company, board structure and composition, dedication, knowledge, sharing of information with the Board, regular attendance, preparedness & participation, team work, decision making process, Board culture and dynamics, independence, governance, ethics and values, adherence to corporate governance norms, quality of relationship between the Board and Management, their roles, rights, responsibilities in the Company.

Further, pursuant to the provisions of Schedule IV of the Act, the Independent Directors in their separate meeting held 16th March, 2025 reviewed, the performance of the Non-Independent Directors and of the Board as a whole, performance of the Chairman of the Board taking into account the views of all the Directors and the quality, quantity and timeliness of flow of information between the Company management and the Board and its sufficiency for the Board to effectively perform its duties.

31. AUDITORS & AUDIT REPORT:

(a) Statutory Auditors:

Pursuant to the provisions of Sections 139, 141, 142 and all other applicable provisions of the Act read with the Companies (Audit and Auditors) Rules, 2014, (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and upon recommendations of the Audit Committee and Board of Directors of the Company, the Members of the Company at the meeting held on 07th August, 2025, had appointed M/s. Shah Valera & Associates LLP (FRN.-W100238), Chartered Accountants, Ahmedabad, as the Statutory Auditors of the Company for a period of 5 (Five) years from the conclusion of 31st AGM till the conclusion of the 36st AGM and to conduct the statutory audit from the Financial Year 2025-2026 to Financial Year 2030-2031.

The Report of the Statutory Auditors for the Financial Year ended on 31st March, 2026 forms integral part of this Annual Report and does not contain any qualification, reservation or adverse remark and is self-explanatory and unmodified and thus does not require any further clarifications/ comments.

(b) Secretarial Auditors:

Pursuant to Section 204 of the Act read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors has appointed Rupal Patel, Practising Company Secretary Ahmedabad as the Secretarial Auditor of the Company for the Financial Year 2025-26. The Secretarial Audit Report for the Financial Year 2025-2026 in Form MR-3 as furnished by the Auditor is annexed herewith as **Annexure-B** & forms an integral part of Board's Report and it does not contain any qualification, reservation or adverse remark and is self-explanatory and thus does not require any further clarifications/ comments.

Further, the Board of Directors in its board meeting held on 14th August, 2025 has appointed Mrs. Rupal Patel, Practicing Company Secretary, Ahmedabad as Secretarial Auditors of the Company for period of five years commencing from financial year 2025-26. Further, the Company has received consent letter regarding such appointment in accordance with the applicable provisions of the Act and Rules framed thereunder.

(c) Internal Auditors:

Pursuant to Section 138 of the Act, the Board of Directors in their meeting held on 14th August, 2025 has appointed M/S. Bhavesh D Shah & Co., Chartered Accountant, (Firm Registration No. 135925W) as an internal auditor of the company for FY 2025-2026. The Audit Committee and Board has reviewed the Internal Audit Report.

(d) Reporting of Frauds:

There was no instance of fraud during the year under review, which required the Statutory Auditors to report to the Audit Committee and / or Board under Section 143(12) of the Act and Rules framed thereunder.

32. COST RECORDS AND COST AUDIT:

The provisions of the Section 148 of the Act read with Companies (Cost Records and Audit) Rules, 2014 are not applicable to the Company and thus the Company is not required to maintain the Cost Records.

33. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENT UNDER SECTION 186 OF THE COMPANIES ACT 2013:

Pursuant to Section 186 of the Act, disclosure on particulars relating to loans, advances, guarantees and investments are provided as part of the financial statements.

34. MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

Pursuant to Regulation 34 of the Listing Regulations, the Management's Discussion and Analysis report of the Company which forms an integral part of this Report is annexed as **Annexure-C**.

35. STATEMENT CONCERNING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE COMPANY:

Risk management is embedded in your company's operating framework. Your company believes that managing risk helps in maximizing returns. The company's approach to addressing business risk is comprehensive and includes periodic review of such risks and a framework for mitigating controls and reporting mechanism of such risks. The risk management framework is reviewed periodically by the Board and the Audit Committee. Some of the risks that the company is exposed to are:

Commodity Price Risks:

The Company is exposed to the risk of price fluctuation of raw material as well as finished goods. The company proactively manages these risks through forward booking, Inventory management and proactive vendor development practices. The Company's reputation for quality, product differentiation and service, coupled with existence of powerful brand image with robust marketing network mitigation the impact the impact of price risk on finished goods.

Regulatory Risks:

The company is exposed to risks attached to various statutes and regulations including the company Act. The company is mitigating these risks through regular review of legal compliances carried out through internal as well as external compliance audits.

Human Resources Risks:

Retaining the existing talent pool and attracting new talent are major risks. The company has initialed

various measures including rolling out strategic talent management system, training and integration of learning and development activities.

Strategic Risks:

Emerging businesses, capital expenditure for capacity expansion, etc., are normal strategic risk faced by the company. However, the company has well-defined processes and procedures for obtaining approvals for investments in new business and capacity expansion etc.

36. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES REFERRED TO IN SECTION 188 OF THE COMPANIES ACT, 2013:

During the Financial Year 2025-2026, no transactions entered into by the Company with related parties under Section 188(1) of the Act were in the ordinary course of business. Hence AOC-2 is not applicable to the Company.

37. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

(A) Conservation of energy and Technology absorption

Pursuant to provisions of Section 134(3)(m) of the Act the particulars in respect of conservation of energy and technology absorption are not applicable to the Company considering the nature of activities undertaken by the Company during the year under review.

(B) Foreign exchange earnings and Outgo

There were no foreign exchange earnings and outgo during the year under review.

38. DEPOSITS:

During the year under review the Company has not accepted any deposits from the public falling under the ambit of Section 73 of the Act and there are no outstanding deposits in terms of the Companies (Acceptance of Deposits) Rules, 2014.

39. VIGIL MECHANISM:

In compliance with the provisions of Section 177(9) & (10) of the Act and Regulation 22 of the Listing Regulations, the Company has a well-established Vigil Mechanism/ Whistle Blower Policy for providing a formal mechanism for all employees of the Company to approach Chairman of the Audit Committee of the Company and make protective disclosures about the unethical behavior, actual or suspected fraud and violation of the Company's Code of Conduct and Business Ethics. Under the Policy, each employee of the Company has an assured access to the Chairman of the Audit Committee. The Vigil Mechanism/Whistle Blower Policy is displayed on the website of the Company at <https://kashyaptelemedicines.com/investor-relations/vigil-mechanism/>

40. CODE OF CONDUCT:

Pursuant to the provisions of Regulations 8 & 9 of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Board of Directors has formulated, implemented and has in place a comprehensive "Code of Fair Disclosure of Unpublished Price Sensitive Information" & "Code of Conduct for Prevention of the Insider Trading" (hereinafter known as "Codes of Conduct") for regulating, monitoring and reporting the trading by Designated Persons of the Company and their immediate relatives which exemplifies the spirit of good ethics and governance and is applicable to the Designated Personnel's of the Company which includes Promoters, Promoter Group, KMPs, Directors, Senior Management and such other employees of the Company and others in fiduciary relationships and as may be approved by the Board of Directors, from time to time, based on the fact of having access to unpublished price sensitive information. The said Codes lay down guidelines advising the Designated Personnel on procedures to be followed and disclosures to be made while dealing with the securities of the Company.

Further the Board Members and Senior Management personnel have affirmed compliance with the Code

of Conduct. A declaration in regard to compliance with the Code of Conduct for the Financial Year 2025-2026 has been received by the Company from the Managing Director.

The "Code of Fair Disclosure of Unpublished Price Sensitive Information" is placed on the website of the Company at

<https://kashyaptele-medicines.com/wp-content/uploads/2019/05/Code-of-fair-disclosure-of-UPSI.pdf>

41. INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:

The Company's Internal Financial Control Systems commensurate with the nature of its business, the size and complexity of its operations and such internal financial controls with reference to the financial statements are adequate. The Board has adopted policies and procedures for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of fraud, error reporting mechanisms, the accuracy and completeness of the accounting records and the timely preparation of reliable financial disclosures.

The Company has devised systems to ensure compliance with the provisions of all applicable laws to the Company. During the year under review, the Audit Committee, the Statutory Auditors and top management of the Company has ensured and reviewed the adequacy of internal control system in the Company, its compliance with operating systems, accounting procedures and policies of the Company. Significant Audit observations and corrective actions, if any, thereon were presented before the Board for their review.

42. EMPLOYEE RELATIONS:

Employee relations throughout the Company were harmonious. The Board wishes to place on record its sincere appreciation of the devoted efforts of all employees in advancing the Company's vision and strategy to deliver good performance.

43. CORPORATE SOCIAL RESPONSIBILITY:

The provisions of Corporate Social Responsibility are not applicable to the Company as the Company does not come under the ambit of Section 135 of the Act read with Companies (Corporate Social Responsibility Policy) Rules, 2014.

44. CORPORATE GOVERNANCE REPORT:

Pursuant to Regulations 15 (2) and 34(3) read with Schedule V of the Listing Regulations, report on Corporate Governance is not applicable to the Company for the Financial Year 2025-2026 as the paid up equity share capital and net worth of the Company does not exceed Rs. 10 crores and Rs. 25 crores respectively as on the last day of previous Financial Year ended on 31st March, 2026. Further the Company has intimated BSE regarding non applicability of Corporate Governance on quarterly basis.

45. LISTING OF SHARES

The Equity Shares of the Company are listed on the BSE Limited (BSE) with scrip code No. 531960. The annual listing fee up to the Financial Year 2025-2026 has been paid to BSE Limited. Further, the Company regularly complies with the provisions of the Listing Regulations from time to time.

46. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:

There were no significant / material orders passed by the regulators or courts or tribunals during the Financial Year 2025- 2026, impacting the going concern status and Company's operations in future.

The BSE Limited vide its email dated 22nd February, 2024 imposed fine of Rs. 1,08,560/- (Rupees One Lakh Eight Thousand Five Hundred Sixty Only) (including GST) concerning the non-compliance of applicable provisions of Regulation 6(1) of the Listing Regulations by the Company. In this regards, the Company has submitted the necessary clarifications to the BSE Limited that the Company is well in compliance with the said provisions and no such non-compliance has been incurred. Additionally,

the Company has also filed the waiver application to BSE Limited for waiving the aforesaid fine and which was approved by the BSE Limited. Further the BSE Limited vide its email dated 20th November, 2025 imposed fine of Rs.17,700/- (Rupees Seventeen Thousand Seven Hundred Only) (including GST) concerning the non-compliance of applicable provisions of Regulation 6(1) of the Listing Regulations, the Company has paid the fine on 16th December, 2025.

47. SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has maintained in place policy on Prevention, Prohibition and Redressal of Sexual Harassment for women at workplace in accordance with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The policy has set guidelines on the redressal and enquiry process that is to be followed by complainants, whilst dealing with issues related to sexual harassment at the work place. During the year, the Company has neither received any complaints nor has any pending complaints under the said Act.

48. MATERNITY BENEFIT PROVIDED BY THE COMPANY UNDER MATERNITY BENEFIT ACT 1961:

The Company declares that it has duly complied with the provisions of the Maternity Benefit Act, 1961. All eligible women employees have been extended the statutory benefits prescribed under the Act, including paid maternity leave, continuity of salary and service during the leave period, and post-maternity support such as nursing breaks and flexible return-to-work options, as applicable. The Company remains committed to fostering an inclusive and supportive work environment that upholds the rights and welfare of its women employees in accordance with applicable laws.

49. COMPLIANCE WITH SECRETARIAL STANDARDS ISSUED BY THE INSTITUTE OF COMPANY SECRETARIES OF INDIA (ICSI):

The Company regularly complies with the provisions of the applicable Secretarial Standards issued by the ICSI.

50. DETAILS OF SETTLEMENT DONE WITH BANKS OR FINANCIAL INSTITUTIONS:

During the year under review and prior periods, the Company has not taken any loan from banks or financial Institutions, accordingly there exist no such requirement of valuations and one time settlement, hence disclosure of details of difference between amount of the valuation done at the time of one time settlement and the valuation done while taking loan from the banks or financial institutions along with the reason thereof is not applicable to the Company.

51. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE FINANCIAL YEAR:

During the year under review, your Company has neither made any application nor any proceedings were initiated/pending against the Company under the Insolvency and Bankruptcy Code, 2016 as at the Financial Year ended on 31st March, 2026.

52. ACKNOWLEDGEMENT:

The Directors take this opportunity to thank the members for their cooperation and support to the Company and look forward for their continued support in future. The Directors also thank all the business associates, Statutory Authorities & Stock Exchange for their continued support during the year. The Directors place on record their appreciation for the hard work put in by the employees of the Company.

For and on behalf of Board of Directors of
June Industries Limited
(Formerly Known as Kashyap Tele-Medicines Limited)

Date : 04th July, 2026
Place : Navi Mumbai

Sd/-
Mr. Kalpesh Bipin Sheth
Managing Director
DIN: 00405151

Registered Office and Corporate Office:
Unit No.22 & 23, Hasti Industrial Premises Co Op Soc Ltd,
Plot No R-798, Mahape, Mi, Dc, Thane, Navi Mumbai, Maharashtra, India, 400701
CIN: L46497MH1995PLC085738
Email Id: investors@june4gmp.com

ANNEXURE-A TO BOARD'S REPORT

- (A) Details Pertaining to Remuneration as Required under section 197(12) of the Companies Act, 2013, Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 read with the Companies (Appointment and Remuneration of Managerial Personnel) Amendments Rules, 2016

1	The Ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial Year 2025-2026.	Name	Ratio to mean remuneration
		Mr. Amit Agrawal Mr. Raghav Agarwal Mrs. Amrita Khetan Mr. Mayank Khetan Ms. Surabhi Agrawal Mr. Devkinandan Sharma Mr. Kalpesh Bipin Sheth Mrs. Heena Kalpesh Sheth Mr. Samir Ambavi Mr. Hardik Bauva Mr. Hiren Mehta Mr. Mandar Jain	Ratio of Remuneration is Nil because No remuneration was paid to any of the Director of the Company during the F.Y. 2025- 2026
2	The Percentage increase in remuneration of each Director, Chief Financial Officer, Company Secretary or Manager (if any) in the Financial Year 2025-2026.	Director/ Cheif Financial Officer/ Company Secretary	% increase/(decrease) in remuneration
		Director	NA
		Mr. Raghav Agrawal- Cheif Financial Officer Mr. Anirudh Shah - Cheif Financial Officer	There was no increase in remuneration during the Financial Year 2025-2026
		Company Secretary- CS Jyoti Sahu Company Secretary- CS Varsha Sawant	423.84%
3	Percentage increase/decrease in the median remuneration of employees in the Financial Year 2025-2026.	During Financial Year 2025-2026, the percentage increase/ (decrease) in the median remuneration of employees as compared to previous year was approximately 423.84%	

4	Number of permanent employees on the roll of the Company.	There were 3 employees as on 31 st March, 2026.
5	**Average percentile increase/(decrease) in salaries of Employees other than managerial Personnel.	The average percentile increase in salaries of Employees other than Managerial Personnel is 4.33% on account of increment provided to employee during the year. There was no other exceptional circumstance for increase in remuneration for employees other than managerial personnel in the last Financial year.
6	Affirmation that the remuneration is as per the remuneration policy of the Company.	It is hereby affirmed that the remuneration paid during the year is as per the Remuneration Policy of the Company.

Note:

** Managerial Personnel includes MD, CFO& CS which has been excluded from calculation of Average Percentile.

(B) Details Pertaining to Remuneration as Required under section 197(12) of the Companies Act, 2013, Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 read with the Companies (Appointment and Remuneration of Managerial Personnel) Amendments Rules, 2016.

(i) Details of top 10- employees in terms of remuneration drawn during the financial year 2025-2026:

Employee Name	Designation	Remuneration	Nature of employment, whether contractual or Otherwise	Qualifications and experience	Date of commencement of employment	Previous employment and designation	The percentage of equity shares held by the employee	Relation with any direct or & Manager
Jyoti Sahu	Company Secretary & Compliance Officer	11000	Permanent	Company Secretary	27-02-2024	Century Enka Limited as Officer (Legal & Secretarial)	Nil	No Relation with any Director and Manager
CS Varsha Sawant	Company Secretary & Compliance Officer	180000	Permanent	Company Secretary	21-07-2025		Nil	No Relation with any Director and Manager

Anirudh Shah	CFO & Director	225000	Permanent		21-07-2025	-	Nil	No Relation with any Director and Manager
--------------	----------------	--------	-----------	--	------------	---	-----	---

- (ii) **Employment throughout the financial year and was in receipt of remuneration for that year which, in the aggregate, was not less than one crore and two lakh rupees:**

For the Financial Year 2025-2026, it is hereby declared that there was no such employee.

- (iii) **Employment for a part of the financial year, was in receipt of remuneration for any part of that year, at a rate which, in the aggregate, was not less than eight lakh and fifty thousand rupees per month:**

For the Financial Year 2025-2026, it is hereby declared that there was no such employee.

- (iv) **Employed throughout the financial year or part thereof, was in receipt of remuneration in the year which, in the aggregate or at a rate which in the aggregate was in excess of that drawn by the Managing Director or Whole time Director or Manager and holds by himself or along with his spouse and dependent children, not less than 2% of the equity shares of the company:**

For the Financial Year 2025-2026, it is hereby declared that there was no such employee.

ANNEXURE-B TO BOARD'S REPORT

Form No. MR-3

SECRETARIAL AUDIT

REPORT

FOR THE FINANCIAL YEAR ENDED ON 31ST MARCH, 2026

*[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of
The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]*

To,

The Members

JUNE INDUSTRIES LIMITED

(FORMERLY KNOWN AS KASHYAP TELE-MEDICINES LIMITED)

Regd. Off: Unit No.22 & 23, Hasti Industrial Premises Co-Op Soc Ltd,

Plot No R-798, Mahape, MI,DC, Thane,Navi Mumbai, Ghansoli,

Thane, Rabale, Maharashtra, India, 400701

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **JUNE INDUSTRIES LIMITED (FORMERLY KNOWN AS KASHYAP TELE-MEDICINES LIMITED)** (hereinafter called "the Company"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives, during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the Financial Year ended on 31st March, 2026 has complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance- mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the Financial Year ended on 31st March, 2026 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;

- (d) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;
- (e) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021;
- (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021;
- (h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; and
- (i) The Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018

However, it has been found that there were no instances requiring compliance with the provisions of the laws indicated at point (c), (d), (e), (g) and (h) of para (v) mentioned hereinabove during the period under review.

- (vi) We further report that having regard to the compliance management system prevailing in the Company for other applicable laws, we were given to understand that there are no sector specific laws applicable to the company and therefore we have not verified compliance management system for the same.

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015;

BSE had sent notice for imposition of fine amounting to Rs. 1,08,560 including GST for non-compliance with requirement to appoint qualified company secretary as the compliance officer for the quarter ended on December, 2023 as per requirements of Regulation 6 (1). The company has made representation for waiver of the same vide letter dated 7th March, 2024 on the grounds that the company had complied with the provisions of Regulation 6 (1), the same has been waived by the BSE Limited. Further the BSE Limited vide its email dated 20th November, 2025 imposed fine of Rs.17,700/- (Rupees Seventeen Thousand Seven Hundred Only) (including GST) concerning the non-compliance of applicable provisions of Regulation 6(1) of the Listing Regulations, the Company has paid the fine on 16th December, 2025.

June Enterprises Private Limited has acquired 1,21,81,118 (25.53%) out of actual open offer of 1,24,07,720 equity shares constituting 26%. This Offer is triggered in compliance with the provisions of Regulations 3(1), and 4 of the SEBI (SAST) Regulations, pursuant to the execution of the Share Purchase Agreement dated Wednesday, March 05, 2025, wherein the Acquirer has agreed to acquire 1,68,72,900 Sale Shares, representing 35.35% of the Voting Share Capital of the Target Company from the Selling Promoter Shareholders, namely being, Mr. Jitendra Tarachand Agrawal (Selling Promoter Shareholder 1), Mr. Amit Yamunadutt Agarwal (Selling Promoter Shareholder 2), Mr. Radheshyam Tarachand Agrawal (Selling Promoter Shareholder 3), Ms. Yamunadutt Amilal Agrawal (Selling Promoter Shareholder 4), and M/s. Jindal Worldwide Ltd (Selling Promoter Shareholder 5) at a negotiated price of ₹1.50/- per Sale Share, aggregating to an amount of ₹2,53,09,350.00/-, payable subject to the terms and conditions specified in the said Share Purchase Agreement. Post Open offer June Enterprises Private Limited hold 2,90,54,018 equity shares constituting 60.88% under promoter category in Kashyap Tele-Medicines Limited. And accordingly, June Enterprise Limited become Holding company in accordance with section 2(46) of the companies act, 2013 (public announcement filed at www.bseindia.com on 25th June, 2025).

During the period under review the Company has endeavored to establish the compliance management system to adhere to the provisions of the Act, Rules, Regulations, Guidelines, Standards, mentioned hereinabove.

We have relied on the representations made by the Company and its officers for systems and mechanisms formed by the Company for compliances of the laws and regulations mentioned hereinabove as applicable to the Company.

We further report that, the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. During the year under review, Ms. Jyoti Sahu resigned from the post of Company Secretary and Compliance Officer of the Company w.e.f. 05th April, 2025 and Ms. Varsha Sawant was appointed as a Company Secretary and Compliance officer of the Company w.e.f. 21st July, 2025.

The company has a system of sending notice to all directors to schedule the Board Meetings, agenda and detailed notes on agenda at least seven days in advance, and a system for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes, wherever required.

We further report that, the company has endeavored to establish adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period of the Company there were no specific events / actions having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc.

Place: Ahmedabad
Date: 14th July, 2026

Rupal Patel,

Practising Company Secretary
FCS No: F6275
CP No.: 3803
PR No.: 702/2020
UDIN: F006275H000832870

Note: This report is to be read with our letter of even date which is annexed as Annexure A and forms an integral part of this report.

ANNEXURE - A

To,
The Members
JUNE INDUSTRIES LIMITED
(FORMERLY KNOWN AS KASHYAP TELE-MEDICINES LIMITED)
Regd. Off: Unit No.22 & 23, Hasti Industrial Premises Co-Op Soc Ltd,
Plot No R-798, Mahape, MI,DC, Thane,Navi Mumbai, Ghansoli,
Thane, Rabale, Maharashtra, India, 400701

Maharashtra, India Sir,

Sub: Secretarial Audit Report for the Financial Year ended on 31st March, 2026.

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

Place: Ahmedabad
Date: 14th July, 2026

Rupal Patel,

Practising Company Secretary
FCS No: F6275
CP No.: 3803
PR No.: 702/2020
UDIN: F006275H000832870

ANNEXURE – C TO BOARD'S REPORT
MANAGEMENT DISCUSSION AND ANALYSIS REPORT

OVERVIEW OF COMPANY:

June Industries Limited (Formerly known as Kashyap Tele-Medicines Limited) is a public limited company incorporated in India and listed on BSE Limited. During the financial year, the Company has strategically shifted its business focus from Information Technology and Software Services to the trading of pharmaceutical, hygiene and cleanroom products. This strategic transformation aligns the Company with the growing healthcare and pharmaceutical distribution sector in India and enables it to capitalize on emerging opportunities in the pharmaceutical supply chain. The Company has its registered office in Navi Mumbai, Maharashtra, and its corporate office in Ahmedabad, Gujarat. The Company is committed to building a sustainable pharmaceutical trading business by emphasizing regulatory compliance, quality products, efficient distribution and customer satisfaction.

1. INDUSTRY STRUCTURE AND DEVELOPMENT:

India continues to be one of the fastest-growing pharmaceutical markets globally and is widely recognized as the "Pharmacy of the World." The Indian pharmaceutical industry has established itself as a leading producer of generic medicines, vaccines and Active Pharmaceutical Ingredients (APIs), supplying medicines to more than 200 countries. Supported by a strong manufacturing base, favorable government policies, increasing healthcare awareness and growing domestic demand, the Indian pharmaceutical market continues to demonstrate resilient growth.

The Indian pharmaceutical market is estimated to have crossed USD 65 billion during FY 2025-26 and is expected to reach nearly USD 130 billion by 2030, driven by increasing healthcare expenditure, rising life expectancy, expansion of health insurance coverage and increasing prevalence of chronic diseases. The Government of India's initiatives such as Ayushman Bharat, Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Pradhan Mantri Bhartiya Janaushadhi Pariyojana and continued investment in healthcare infrastructure are expected to create significant opportunities across the pharmaceutical value chain.

The pharmaceutical wholesale trading industry plays a vital role in ensuring the uninterrupted availability of medicines across hospitals, pharmacies, healthcare institutions and retail distribution networks. The sector has witnessed increasing demand owing to expansion of organized retail pharmacies, growth of e-pharmacies, improvement in logistics infrastructure and implementation of digital supply chain management systems. Increasing emphasis on quality assurance, traceability, inventory optimization and regulatory compliance has further strengthened the organized pharmaceutical distribution ecosystem.

During the year under review, June Industries Limited commenced its transition towards pharmaceutical products trading. The Company intends to establish a diversified portfolio comprising pharmaceutical formulations, hygiene products and cleanroom consumables while leveraging its management capabilities and business network. Although the Company is presently in the initial stage of business transformation, management believes that the long-term fundamentals of the Indian pharmaceutical distribution industry provide substantial opportunities for sustainable growth and value creation.

2. OPPORTUNITIES:

1. Rapid Growth in Indian Pharmaceutical Market

India's pharmaceutical industry continues to witness robust growth supported by increasing healthcare expenditure, rising disposable income, greater health awareness and expanding access to healthcare

facilities. The pharmaceutical wholesale distribution sector is expected to benefit significantly from increasing demand for quality medicines and healthcare products across urban as well as rural markets.

2. Expansion of Organized Pharmaceutical Distribution

The pharmaceutical distribution industry is gradually shifting from fragmented unorganized players to organized wholesale distributors who comply with regulatory standards, maintain product traceability and ensure timely deliveries. This transition provides significant opportunities for professionally managed companies to expand their customer base and strengthen market presence.

3. Government Healthcare Initiatives

Government initiatives such as Ayushman Bharat, Jan Aushadhi Scheme, expansion of healthcare infrastructure and increasing allocation towards healthcare are expected to enhance pharmaceutical consumption across the country. Growing institutional demand from hospitals, clinics and healthcare providers is likely to support long-term business growth.

4. Increasing Demand for Hygiene and Cleanroom Products

Growing awareness regarding infection prevention, workplace hygiene, pharmaceutical manufacturing standards and healthcare safety has significantly increased the demand for hygiene products and cleanroom consumables. This presents an attractive opportunity for the Company to diversify its product portfolio and cater to specialized customer segments.

5. Digitalization of Pharmaceutical Supply Chain

Increasing adoption of ERP systems, digital inventory management, online procurement platforms and technology-driven logistics is improving supply chain efficiency across the pharmaceutical industry. The Company intends to leverage digital solutions to optimize procurement, inventory management and customer servicing, thereby enhancing operational efficiency and competitiveness.

CHALLENGES:

The Indian pharmaceutical wholesale trading industry continues to offer significant growth opportunities; however, it is also exposed to several operational, regulatory and economic challenges. The Company continuously evaluates these risks and adopts appropriate measures to strengthen its business model and ensure sustainable growth.

1. Regulatory Compliance

The pharmaceutical industry is one of the most regulated sectors in India. Wholesale distributors are required to comply with various regulations relating to drug licensing, storage conditions, product traceability, GST compliance and quality standards prescribed under the Drugs and Cosmetics Act and related regulations. Any changes in regulatory requirements may increase compliance costs and impact operations.

2. Pricing Pressure

The pharmaceutical market is highly competitive with increasing pressure on product pricing due to

government regulations under the Drug Price Control Order (DPCO), competition among distributors and procurement by institutional buyers. Sustaining profitability while maintaining competitive pricing remains a key challenge.

3. Supply Chain Disruptions

The pharmaceutical distribution business depends upon timely procurement and uninterrupted supply of products from manufacturers. Any disruption arising from raw material shortages, transportation bottlenecks, geopolitical developments or manufacturing delays may impact product availability and customer service.

4. Working Capital Management

The wholesale pharmaceutical business generally requires adequate working capital to maintain inventories and extend credit to customers. Efficient inventory planning, receivable management and cash flow monitoring are essential for maintaining liquidity and operational efficiency.

5. Intense Competition

The Indian pharmaceutical distribution market comprises several organized and unorganized players competing on pricing, product availability and customer service. Continuous improvement in operational efficiency, customer relationships and product portfolio will be essential to maintain competitiveness.

Despite these challenges, the Company believes that its strategic focus, prudent financial management and customer-centric approach will enable it to successfully capitalize on emerging opportunities within the pharmaceutical distribution sector.

STRENGTH:

June Industries Limited is in the process of establishing its presence in the pharmaceutical wholesale trading industry. The Company's key strengths are expected to support its long-term growth and business sustainability.

1. Strategic Business Transformation

The Company has successfully realigned its business objectives from Information Technology to pharmaceutical products trading, thereby entering a sector with strong long-term growth potential supported by increasing healthcare expenditure and rising demand for pharmaceutical products.

2. Asset-Light Business Model

The Company's wholesale trading model enables it to operate with comparatively lower capital expenditure requirements than pharmaceutical manufacturing businesses. This provides operational flexibility and allows management to focus on business expansion and efficient utilization of financial resources.

3. Experienced Management

The Company is led by an experienced management team committed to maintaining high standards of corporate governance, regulatory compliance and ethical business practices. Management continues to

evaluate business opportunities for expanding the Company's product portfolio and customer base.

4. Focus on Customer Satisfaction

The Company intends to build long-term relationships with pharmaceutical manufacturers, distributors, hospitals, healthcare institutions and retail customers by ensuring timely delivery, quality products and reliable customer support.

5. Financial Discipline

The Company continues to maintain a debt-free capital structure and adopts a prudent approach towards financial management. This provides financial flexibility for future expansion and enables the Company to pursue growth opportunities in a disciplined manner.

OVERALL REVIEW OF COMPANY

During the Financial Year 2025-26, the Company undertook a significant strategic transformation by changing its principal business activity from Information Technology and Software Services to the trading of pharmaceutical, hygiene and cleanroom products. This transition marks an important milestone in the Company's long-term growth strategy and positions it to participate in one of India's fastest-growing industries.

The Company is presently in the initial phase of developing its pharmaceutical trading business and is focused on establishing reliable sourcing arrangements, strengthening its distribution network and building long-term relationships with manufacturers, healthcare institutions and retail customers. Management believes that India's expanding healthcare infrastructure, increasing pharmaceutical consumption and supportive government initiatives provide a strong foundation for sustainable future growth.

The Company intends to gradually expand its product portfolio to include pharmaceutical formulations, hygiene products, cleanroom consumables and other healthcare-related products, while maintaining strict compliance with applicable regulatory requirements. The management remains committed to improving operational efficiency, strengthening internal processes and creating long-term value for all stakeholders.

OPPORTUNITIES, THREAT, RISKS AND CONCERNS

The Indian pharmaceutical industry continues to offer attractive long-term growth opportunities driven by increasing healthcare expenditure, growing prevalence of chronic diseases, rising awareness regarding preventive healthcare and expansion of healthcare infrastructure across the country. The pharmaceutical wholesale distribution sector is expected to benefit from increasing demand for quality medicines, organized supply chains and digital transformation of healthcare services.

However, the business also faces certain risks including changes in regulatory policies, pricing controls, supply chain disruptions, increasing competition, fluctuations in procurement costs and changing customer preferences. The Company continuously monitors these developments and adopts appropriate risk mitigation measures through effective procurement planning, regulatory compliance, efficient inventory management and prudent financial controls.

The Company also recognizes risks relating to customer credit, liquidity management and operational continuity. Accordingly, emphasis is placed on maintaining adequate internal controls, strengthening

vendor relationships and ensuring timely monitoring of receivables and working capital.

Management remains confident that the Company's strategic repositioning into pharmaceutical trading, combined with disciplined execution and sound governance practices, will enable it to successfully address these challenges and capitalize on emerging opportunities.

FUTURE OUTLOOK:

The long-term outlook for the Indian pharmaceutical industry remains positive, supported by favourable demographics, increasing healthcare awareness, rising income levels and continued government focus on healthcare infrastructure. The pharmaceutical wholesale trading sector is expected to grow steadily with increasing demand from hospitals, retail pharmacies, healthcare institutions and organized distribution channels.

June Industries Limited intends to strengthen its position by expanding its product portfolio, developing strategic relationships with reputed manufacturers and suppliers and enhancing operational efficiency through technology-driven business processes. The Company also proposes to explore opportunities in specialized healthcare products, hygiene solutions and cleanroom consumables to diversify its revenue streams.

Management remains committed to building a sustainable and scalable pharmaceutical trading business through disciplined financial management, customer-centric operations, regulatory compliance and continuous improvement in business processes. The Company believes that its strategic transformation provides a strong platform for long-term growth and sustainable shareholder value creation.

3. FINANCIAL CONDITION AND OPERATIONAL PERFORMANCE:

a. Share Capital

The Company presently has one class of equity shares. The Authorized Share Capital of the Company is ₹15,00,00,000 divided into 15,00,00,000 Equity Shares of ₹1/- each. The issued, subscribed and paid-up share capital of the Company as on 31st March, 2026 stood at ₹4,77,22,000, comprising 4,77,22,000 Equity Shares of ₹1/- each.

There was no change in the issued, subscribed and paid-up share capital during the financial year under review.

b. Shareholder Funds

The total Shareholders' Funds of the Company stood at ₹17.88 Lakhs as on 31st March, 2026 as against ₹63.95 Lakhs as on 31st March, 2025. The reduction in shareholders' funds was primarily attributable to the loss incurred during the year under review.

c. Profit & Loss account

The Company reported a Loss after Tax (PAT) of ₹46.06 Lakhs for the financial year ended 31st March, 2026 as against a marginal loss in the previous financial year. The loss was mainly attributable to higher employee benefit expenses, administrative costs and penalties incurred during the year.

d. Fixed Assets

As per the audited Financial Statements for the year ended 31st March, 2026, the Company does not own any significant fixed assets. The Company's operations continue to remain asset-light, enabling greater operational flexibility and efficient utilization of financial resources.

e. Net Worth

The Return on Net Worth (RONW) for the financial year ended 31st March, 2026 stood at (4.69%), reflecting the loss incurred during the year.

f. Income

The revenue from operations for the financial year ended 31st March, 2026 stood at ₹19.70 Lakhs. The Company's operating revenue primarily comprised income from Projects & Services amounting to ₹3.60 Lakhs and Software Sales amounting to ₹15.60 Lakhs, reflecting the Company's continued focus on technology-driven software solutions and digital services.

g. Earnings before Interest, Tax and Depreciation (EBITDA)

The Company reported an EBITDA loss of ₹46.06 Lakhs during the financial year ended 31st March, 2026 as compared to a nominal EBITDA loss in the previous year. The decline was primarily due to increased operating expenses and employee-related costs during the year.

h. Earnings per share (EPS)

The Basic and Diluted Earnings per Share (EPS) for the financial year ended 31st March, 2026 stood at ₹(0.097) per equity share as against ₹(0.000) per equity share in the previous year.

4. SEGMENT WISE / PRODUCT WISE PERFORMANCE:

The Company presently operates in a single business segment. Accordingly, segment-wise reporting is not applicable. Following the change in the Company's main object, the management is focusing on establishing and expanding its pharmaceutical products trading business. As the business grows, the Company shall review the need for segment reporting in accordance with the applicable Accounting Standards.

5. RISKS, CONCERNS AND THREATS:

The pharmaceutical wholesale trading business is exposed to various business, financial and operational risks including regulatory compliance risk, supply chain disruptions, inventory management risk, customer credit risk, liquidity risk, pricing pressure, competition, product quality risk and changes in healthcare regulations.

The Company continuously evaluates these risks through an effective risk management framework and adopts appropriate mitigation measures including vendor evaluation, prudent inventory management, monitoring of receivables, strengthening internal controls and maintaining compliance with applicable laws and regulations. The Company also focuses on developing long-term relationships with reliable suppliers and customers to minimize operational risks.

Management believes that timely identification and effective management of these risks will enable the Company to achieve sustainable business growth while protecting stakeholders' interests.

6. INTERNAL CONTROL SYSTEM AND THEIR ADEQUACY:

The Company has aligned its current systems of internal financial control with the requirement of Section 134(5)(e) of the Companies Act, 2013. It includes policies and procedures adopted by the Company for ensuring orderly and efficient conduct of its business, thereby covering not only the controls pertaining to financial statements but also include strategic and operational controls pervasive across the entire business. The Company has an adequate system of internal financial controls commensurate with the size and nature of its business operations. The internal control framework is designed to ensure orderly and efficient conduct of business, safeguarding of assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records and timely preparation of reliable financial information.

The Audit Committee periodically reviews the adequacy and effectiveness of the internal control systems, internal audit findings and compliance with applicable laws and regulations. Appropriate corrective actions

are taken wherever necessary to strengthen the overall control environment.

The Statutory Auditors have also reviewed the adequacy of internal financial controls over financial reporting as part of their audit procedures.

7. MATERIAL DEVELOPMENTS IN HUMAN RESOURCES / INDUSTRIAL RELATIONS:

The Company firmly believes that its employees are one of its most valuable assets and recognizes the importance of developing a competent, motivated and professional workforce.

During the financial year under review, the Company continued to maintain cordial industrial relations. Management remains committed to providing a transparent, performance-oriented and healthy working environment that encourages professional development, teamwork and ethical conduct.

The Company continues to strengthen its organizational capabilities in line with its transition into pharmaceutical trading and remains focused on attracting and retaining skilled professionals to support future business growth.

8. DETAILS OF SIGNIFICANT CHANGES (I.E. CHANGE OF 25% OR MORE AS COMPARED TO THE IMMEDIATELY PREVIOUS FINANCIAL YEAR) IN KEY FINANCIAL RATIOS, ALONG WITH DETAILED EXPLANATIONS THEREFOR:

Details of Key Financial Ratios and any change in Return on Net Worth of the Company including explanations therefore are given below:

Ratio	31 st March, 2026	31 st March, 2025	% change*
Current Ratio	1.40	0.22	5.22%
Debt- Equity Ratio	This ratio is not applicable to the Company as there is no debt raised by the Company		
Debt Service Coverage ratio	This ratio is not applicable to the Company as there is no debt raised by the Company		
Return on Equity ratio	(2.58)	(0.00)	>100%
Inventory Turnover ratio	This ratio is not applicable to the Company as the Company does not hold inventory		
Trade Receivable Turnover Ratio	This ratio is not relevant as there are no major customer balances outstanding in current year and previous year.		
Trade Payable Turnover Ratio	This ratio is not applicable to the Company does not have any trade payables		
Net Capital Turnover Ratio	1.12	(10.53)	(>100%)
Net Profit ratio	(2.34)	(0.00)	(>100%)
Return on Capital Employed	(2.58)	(0.00)	>100%
Return on Investment	This ratio is not applicable as the Company does not have any investment which generate return on investment		

Notes:

The major reason for variation in Current Ratio and Net Capital Turnover Ratio is mainly due to increased payables for expenses.

The major reason for change in profitability and margin related ratios is mainly due to the reason that the profit / (loss) for the current year is impacted due to penalty charged by BSE Limited and increased employee benefit expenses.

* The numbers in brackets represent that the numbers are in negative.

For and on behalf of Board of Directors of
For June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)

Date : 04th July, 2026
Place : Navi Mumbai

Sd/-
Mr. Kalpesh Bipin Sheth
Managing Director
DIN: 00405151

MANAGING DIRECTOR AND CHIEF FINANCIAL OFFICER CERTIFICATION
{For the Financial Year ended 31st March, 2026}

To,
The Board of Directors,
June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)

In pursuance to Regulation 17(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby certify that:

- A. We have reviewed financial statements and the cash flow statement for the year ended 31st March, 2026 and that to the best of our knowledge and belief:
 - 1) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - 2) these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- B. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
- C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have not found any deficiencies in the design or operation of such internal controls.
- D. We further certify that we have indicated to the auditors and the Audit committee that:
 - 1) there have been no significant changes in internal control over financial reporting during the year;
 - 2) there have been no significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - 3) there have been no instances of significant fraud of which they have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For and on behalf of Board of Directors of
For June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)

Date : 04th July, 2026
Place : Navi Mumbai

Sd/-
Mr. Kalpesh Bipin Sheth
Managing Director
DIN: 00405151

Annexure 'B' to the Independent Auditors' report on the Financial Statements of June Industries Limited for the year ended 31 March 2026

(Referred to in paragraph '19.6' under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on the Internal Financial Controls with reference to the aforesaid Financial Statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act').

Opinion

1. We have audited the internal financial controls with reference to the Financial Statements of June Enterprises Limited ('the Company') as at 31 March 2026 in conjunction with our audit of the Financial Statements of the Company for the year ended on that date.
2. In our opinion, the Company has, in all material respects, an adequate internal financial controls with reference to the Financial Statements and such internal financial controls were operating effectively as at 31 March 2026, based on the internal controls over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ('the Guidance Note').

Management's responsibility for Internal Financial Controls

3. The Company's management is responsible for establishing and maintaining internal financial controls based on the internal controls over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's responsibility

4. Our responsibility is to express an opinion on the Company's internal financial controls with reference to the Financial Statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing ('SA'), prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to the Financial Statements. Those SAs and the Guidance Note require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to the Financial Statements were established and maintained and whether such controls operated effectively in all material respects.
5. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to the Financial Statements and their operating effectiveness. Our audit of internal financial controls with reference to the Financial Statements included obtaining an understanding of internal financial controls with reference to the Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error.
6. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to the Financial Statements.

Meaning of Internal Financial Controls with reference to the Financial Statements

7. A Company's internal financial controls with reference to the Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Financial Statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial controls with reference to the Financial Statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Financial Statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the Financial Statements.

Inherent Limitations of Internal Financial Controls with reference to the Financial Statements

8. Because of the inherent limitations of internal financial controls with reference to the Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to the Financial Statements to future periods are subject to the risk that the internal financial controls with reference to the Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For Shah Valera & Associates LLP

Chartered Accountants

Firm Registration Number: W100238



Priten B. Shah

Partner

ICAI Membership No: 149028

UDIN: 26149028JWPSDK9499

Place: Mumbai

Date: 20 May 2026

Independent Auditor's Report

To
The Members of
June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)

Report on the audit of the Financial Statements

Opinion

1. We have audited the accompanying Financial Statements of June Industries Limited ('the Company'), which comprise the Balance Sheet as at 31 March 2026, and the Statement of Profit And Loss (including Other Comprehensive Income), Statement of Changes in Equity and Statement of Cash Flows for the year ended on that date, and notes to the Financial Statements, including a summary of material accounting policies and other explanatory information ('the Financial Statements').
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ('Ind AS') and other accounting principles generally accepted in India, of the State of Affairs of the Company as at 31 March 2026, and its Loss and Other Comprehensive Income, Changes in Equity and its Cash Flows for the year ended on that date.

Basis for Opinion


3. We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Financial Statements.

Key Audit Matters

4. Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Financial Statements of the current year. These matters were addressed in the context of our audit of the Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no Key Audit Matters to communicate in our report.

Other Information

5. The Company's Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report/the management report and chairman's statement but does not include the Financial Statements and our auditors' report thereon. The Other Information is expected to be made available to us after the date of this auditor's report



6. Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.
7. In connection with our audit of the Financial Statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated.
8. When we read the Annual Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take appropriate action as applicable under the relevant laws and regulations.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

9. The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act, with respect to the preparation of these Financial Statements that give a true and fair view of the State of Affairs, Loss and Other Comprehensive Income, Changes in Equity and Cash Flows of the Company in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection of the appropriate accounting software for ensuring compliance with applicable laws and regulations including those related to retention of audit logs; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
10. In preparing the Financial Statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
11. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the audit of the Financial Statements

12. Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - 12.1. Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may

involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.


- 12.2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to Financial Statements in place and the operating effectiveness of such controls.
- 12.3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management.
- 12.4. Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- 12.5. Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

13. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
14. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
15. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current year and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matter

16. The Financial Statements of the Company for the year ended 31 March 2025 were audited by Ravi Karia & Associates whose reports dated 23 May 2025 expressed an unmodified opinion on those Financial Statements. Our opinion is not modified in respect of this matter.



Report on Other Legal and Regulatory Requirements

17. As required by the Companies (Auditor's Report) Order, 2020 ('the Order'), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the 'Annexure A' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
18. As required by Section 143(3) of the Act, we report that:
- 19.1. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - 19.2. In our opinion, proper books of accounts as required by law have been kept by the Company so far as it appears from our examination of those books.
 - 19.3. The balance sheet, the statement of profit and loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - 19.4. In our opinion, the aforesaid Financial Statements comply with the Ind AS specified under Section 133 of the Act read with the relevant rules thereunder.
 - 19.5. On the basis of the written representations received from the directors taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2026 from being appointed as a director in terms of Section 164(2) of the Act.
 - 19.6. With respect to the adequacy of the internal financial controls with reference to Financial Statements of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'.
 - 19.7. In our opinion and according to the information and explanations given to us, the Company has not paid any remuneration to its directors during the current year. Accordingly, the provisions of Section 197 of the Act relating to managerial remuneration are not applicable.
19. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
- 20.1. The Company does not have any pending litigations as at 31 March 2026;
 - 20.2. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - 20.3. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - 20.4. The Management has represented, to best of their knowledge and belief, that no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ('Intermediaries'), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ('Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - 20.5. The Management has represented, to best of their knowledge and belief, that no funds have been received by the Company from any person(s) or entity(ies), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company.

Party ('Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- 20.6. Based on such audit procedures, that have been considered reasonable and appropriate in the circumstances, performed by us, nothing has come to our notice that has caused us to believe that the representation under sub clause (i) and (ii) of Rule 11(e), as provided under para 20.4 and 20.5 above, contain any material misstatement.
- 20.7. In our opinion and according to information and explanation given to us, the Company has not declared or paid dividend during the year, accordingly compliance with section 123 of the Act by the Company is not applicable.
- 20.8. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account which have a feature of recording audit trail (edit log) facility, which have operated throughout the year for all relevant transactions recorded in the software. Based on our procedures performed, we did not notice any instance of the audit trail feature being tampered with. Further, where audit trail (edit log) facility was enabled and operated throughout thereafter, we did not come across any instance of audit trail feature being tampered with during the course of our audit.

Additionally, the audit trail has been preserved by the Company as per the statutory requirements for record retention.

For **Shah Valera & Associates LLP**
Chartered Accountants
Firm Registration Number: W100238



Priten B Shah
Partner
ICAI Membership No: 149028
UDIN: 26149028JWPSPDK9499

Place: Mumbai
Date: 20 May 2026

Annexure "A" to the Independent Auditor's Report on the Financial Statements of June Industries Limited for the year ended March 31, 2026

(Referred to in paragraph "18" under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

- i. In respect of the Company's Property, Plant and Equipment and Intangible Assets:
 - (a) The Company does not have any Property, Plant and Equipment or intangible assets during the year. Accordingly, the requirements of clause 3(i) of the Companies (Auditor's Report) Order, 2020 are not applicable to the Company.
- ii.
 - (a) In our opinion and according to the information and explanations given to us, the Company does not have any inventory. Hence this clause is not applicable.
 - (b) In our opinion and according to the information and explanations given to us, the Company has not been sanctioned working capital limits in excess of rupees five crore, in aggregate, from banks or financial institutions which are secured on the basis of security of current assets. Hence this clause is not applicable.
- iii. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any investments in companies and has not made any investments in firms, limited liability partnership or any other parties. The Company has not provided guarantee or security, granted any loans and advances in the nature of loans to Companies during the year. The Company has not provided any guarantee or security, granted any loans or advances in the nature of loans, secured or unsecured, to firms, limited liability partnership or any other parties during the year.
 - (a) Based on the audit procedures carried on by us and as per the information and explanations given to us, the Company has not provided loans or provided advances in the nature of loans to any other entity.
 - (b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion Since no such loan has been given, the terms and conditions do not require reporting.
 - (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, company has not provided guarantee or security, granted any loans and advances in the nature of loans. Hence schedule for repayment is not applicable.
 - (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no overdue amount for more than ninety days in respect of loans given. Further, the Company has not given any advances in the nature of loans to any party during the year.
 - (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted falling due during the year, which has been renewed or extended or fresh loans granted to settle the overdues of existing loans given to same parties.
 - (f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion the Company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment.

- iv. The Company has not granted any loans or made any investment or provided any guarantees or security to the parties covered under section 185 and section 186 of the Act.
- v. In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits or amounts which are deemed to be deposits from the public during the year in terms of directives issued by the Reserve Bank of India or the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the rules framed there under. Accordingly, paragraph 3(v) of the Order is not applicable to the Company.
- vi. As per the provisions of Companies Act, 2013 the company is not liable to maintain any cost records as per section 148(1) hence this clause is not applicable.
- vii. (a) In our opinion and according to the information and explanations given to us, the company is generally regular in depositing with the appropriate authorities amounts deducted/accrued in the books of account in respect of undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax and any other statutory dues.
- According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income-tax, Goods and Services Tax, duty of customs, cess and other material statutory dues were in arrears as at 31 March 2026 for a period of more than six months from the date they became payable.
- (b) In our opinion and according to the information and explanations given to us, we confirm that there were no dues of Income-tax on account of dispute.
- viii. In our opinion and according to the information and explanations given to us and on the basis of our examination of the records of the Company, we confirm that we have not come across any transactions not recorded in the books of account which have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.
- ix. (a) In our opinion, the Company has not taken any loans or other borrowings from financial institutions, banks, accordingly clause 3(ix)(a) of the order is not applicable
- (b) According to the information and explanations given to us and on the basis of our audit procedures, we report that the Company has not been declared willful defaulter by any bank or financial institution or government or any government authority or any other lender.
- (c) In our opinion and according to the information and explanations given to us, the Company has not obtained any term loans during the year. Accordingly, clause 3(ix)(c) of the Order is not applicable.
- (d) The Company has not taken any Short-term Loans
- (e) The Company did not took any funds from its Joint venture and Associates, also the company does not have any subsidiary during the year and hence, reporting under clause (ix), (e) is not applicable.
- (f) The Company did not have Subsidiary, Joint venture and Associates during the year and hence, reporting under clause (ix), (f) is not applicable.
- x. (a) The Company did not raise money by way of initial public offer or further public offer (including debt instruments) during the year.
- (b) The Company has not made any preferential allotment / private placement of shares / fully / partly / optionally convertible debentures during the year.
- xi. (a) In our opinion and according to the information and explanations given to us, there has been no fraud by the Company or any fraud on the Company that has been noticed or reported during the year.

- (b) In our opinion and according to the information and explanations given to us, no report under sub-section (12) of section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.
- xii. (a) In our opinion and according to the information and explanations given to us, the Company is not a Nidhi company. Accordingly, paragraph 3(xii) of the Order is not applicable to the Company.
- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with Sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- xiv. (a) In our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
- (b) We have considered the internal audit reports for the period under audit issued to the Company during the course of our audit.
- xv. According to the information and explanations given to us, in our opinion during the year the Company has not entered into any non-cash transactions with its directors or persons connected with its directors. Accordingly, paragraph 3(xv) of the Order is not applicable to the Company and hence provisions of section 192 of the Act, 2013 are not applicable to the Company.
- xvi. (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.
- (b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.
- (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- (d) According to the information and explanations given to us, the Group does not have any Core Investment Company (CIC) as part of the Group as per the definition of Group contained in the Core Investment Companies (Reserve Bank) Directions, 2016 and hence the reporting under clause (xvi)(d) of the Order is not applicable.
- xvii. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has incurred cash losses of Rs. 46.06 Lakh during the financial year ended March 31, 2026 and cash losses of Rs. 0.03 Lakh during the financial year ended March 31, 2025
- xviii. According to the information and explanations given to us there has been resignation of the statutory auditor during the year. However no issues, objections, or concerns were raised by the outgoing auditors which required our consideration.
- xix. According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance

sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

- xx. The Company is not required to spent amount towards Corporate Social Responsibility (CSR) and therefore, no CSR amount for the year requiring a transfer of Fund specified in Schedule VII to the Companies Act or special account in compliance with provision of sub- section (6) of section 135 of said Act. Accordingly, reporting under clause (xx) of the order is not applicable for the year.
- xxi. The Company did not have Subsidiary, Joint venture and Associates during the year and hence, reporting under clause (xxi) is not applicable.

For Shah Valera & Associates LLP

Chartered Accountants

Firm Registration Number: W100238



Priten B. Shah

Partner

ICAI Membership No: 149028

UDIN: 26149028JWPSDK9499

Place: Mumbai

Date: 20 May 2026

June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Balance Sheet as at March 31, 2026
CIN: L46497MH1995PLC085738

Amount (Rs.) in Lakhs

Particulars	Notes	As at 31st March, 2026	As at 31st March, 2025
Assets			
Non-current assets			
Property, Plant and Equipment		-	-
Capital work in progress		-	-
Financial assets			
- Investments		-	-
- Other financial assets	6	0.34	0.34
Other non-current assets	7	-	65.43
Total non-current assets		0.34	65.77
Current assets			
Inventories		-	-
Financial assets			
- Trade receivables		-	-
- Cash and cash equivalents	8	25.04	0.37
- Investments	9	35.72	-
- Loans		-	-
Current Tax Assets (Net)	10	0.63	0.16
Other current assets		-	-
Total current assets		61.39	0.53
Total assets		61.73	66.30
Equity and liabilities			
Equity			
Equity share capital	11	477.22	477.22
Other equity	12	(459.34)	(413.27)
Total equity		17.88	63.95
Liabilities			
Non Current Liabilities			
Long term borrowings		-	-
Deferred tax liabilities (net)		-	-
Other long term liabilities		-	-
Current Liabilities			
Financial liabilities			
- Short term borrowings		-	-
- Trade Payables		-	-
Total Outstanding dues of micro enterprises and small enterprises			
Total Outstanding dues of creditors other than micro enterprises and small enterprises			
- Other financial liabilities	13	43.85	2.35
Other current liabilities		-	-
Current Tax Liabilities (Net)		-	-
Other Current Liabilities		-	-
Short-Term Provisions		-	-
Current Tax Liabilities (Net)		-	-
Total liabilities		43.85	2.35
Total equity and liabilities		61.73	66.30

The accompanying notes 1 to 27 form an integral part of these financial statements
As per our report of even date

For SHAH VALERA & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.: W100238


Priten B. Shah
(Partner)

Membership No. : 149028

Place: Mumbai
Date: 20/05/2026

For and on behalf of the Board of Directors of
June Industries Limited
(Formerly Known as Kashyap Tele-Medicines Limited)


Mr. Kalpesh Sheth
Managing Director
(DIN: 00405151)


Mrs. Heena K. Sheth
Director
(DIN: 07627681)


CS Varsha Sawant
Company Secretary
(Membership No. A72926)


Mr. Anirudh Shah
CFO

June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Statement of Profit and Loss for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

Amount (Rs.) in Lakhs

Particulars	Notes	For the year ended March 31, 2026	For the year ended March 31, 2025
Income			
Revenue from operations	14	19.70	19.20
Other income	15	1.88	0.00
Total income		21.58	19.20
Expenses			
Employee benefits expense	16	1.91	10.81
Other expenses	17	65.73	8.40
Total expenses		67.64	19.21
Profit/(loss) before exceptional and extraordinary items and tax		(46.06)	(0.01)
Exceptional items		0.00	0.00
Profit before Extraordinary items and tax		(46.06)	(0.01)
Extraordinary items		0.00	0.00
Profit/(loss) before taxes		(46.06)	(0.01)
Tax expense:			
Current tax		0.00	0.00
Tax relating to previous year		0.00	0.02
Income tax expense	18	0.00	0.02
Profit / (Loss) for the period from Continuing Operations		(46.06)	(0.03)
Profit/(loss) from Discontinuing Operations		0.00	0.00
Tax Expense of Discontinuing Operations		0.00	0.00
Profit/(loss) from Discontinuing operations (after tax)		0.00	0.00
Profit / (Loss) for the period		(46.06)	(0.03)
Share of profit / (loss) of Associates			
Minority interest		0.00	0.00
Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates		(46.06)	(0.03)
Other Comprehensive Income			
A. Items that will be/will not be reclassified to profit and loss		0.00	0.00
B. Income tax relating to items that will be / will not be reclassified to profit and loss		0.00	0.00
Total comprehensive income for the period		(46.06)	(0.03)
Earnings per equity share			
Basic and Diluted	19	(0.097)	0.000

The accompanying notes 1 to 27 form an integral part of these financial statements

As per our report of even date

For SHAH VALERA & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.: W100238



Priten B. Shah

(Partner)

Membership No. : 149028



For and on behalf of the Board of Directors of
June Industries Limited

(Formerly Known as Kashyap Tele-Medicines Limited)



Mr. Kalpesh Sheth
Managing Director
(DIN: 00405151)



Mrs. Heena K. Sheth
Director
(DIN: 07627681)



CS Varsha Sawant
Company Secretary
(Membership No. A72926)



Mr. Anirudh Shah
CFO

Place: Mumbai

Date: 20/05/2026

June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Cash Flow Statement for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

Particulars	Amount (Rs.) in Lakhs	
	For the year ended March 31, 2026	For the year ended March 31, 2025
A Cash flow from operating activities:		
Profit before tax	(46.06)	(0.01)
Adjustments		
Interest income	(1.88)	
Operating profit before working capital changes	(47.94)	(0.01)
Adjustments for changes in working capital :		
Change in trade receivables	-	0.60
Change in other receivables	65.43	(7.00)
Change in Current Liabilities & other payables	41.49	(2.17)
Cash flow from/ (used in) operations	58.98	(8.58)
Income taxes paid	(0.47)	0.02
Net cash flow from/(used in) operating activities	58.51	(8.60)
B Cash flow from investing activities:		
Purchase of investments	(35.72)	-
Interest received	1.88	
Net cash (used in)/flow from investing activities	(33.84)	-
C Cash flow from financing activities:		
Net cash (used in)/flow from financing activities:	-	-
Net increase in cash and cash equivalents (A+B+C)	24.67	(8.60)
Cash and cash equivalents at the beginning of the year	0.37	8.97
Cash and cash equivalents at the end of the year	25.04	0.37

The accompanying notes 1 to 27 form an integral part of these financial statements
As per our report of even date

For SHAH VALERA & ASSOCIATES LLP
Chartered Accountants
Firm Registration No.: W100238



Priten B. Shah
(Partner)
Membership No. : 149028



For and on behalf of the Board of Directors of
June Industries Limited
(Formerly Known as Kashyap Tele-Medicines Limited)


Mr. Kalpesh Sheth
Managing Director
(DIN: 00405151)


Mrs. Heena K. Sheth
Director
(DIN: 07627681)


CS Varsha Sawant
Company Secretary
(Membership No. A72926)


Mr. Anirudh Shah
CFO

Place: Mumbai
Date: 20/05/2026

June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Statement of Changes in Equity for the period ended March 31, 2026
CIN: L46497MH1995PLC085738

A. Equity share capital

31st March, 2026

Particulars	Numbers	Amount (Rs.) in Lakhs
At 1st April, 2025	4,77,22,000	477.22
Changes in equity share capital due to prior period errors	-	-
Restated balance as at 1st April, 2023	4,77,22,000	477.22
Changes in equity share capital	-	-
At 31st March, 2026	4,77,22,000	477.22

31st March, 2025

Particulars	Numbers	Amount (Rs.) in Lakhs
At 1st April, 2024	4,77,22,000	477.22
Changes in equity share capital due to prior period errors	-	-
Restated balance as at 1st April, 2022	4,77,22,000	477.22
Changes in equity share capital	-	-
At 31st March, 2025	4,77,22,000	477.22

B. Other equity

31st March, 2026

Particulars	Reserves & Surplus		Total
	Capital Reserve	Retained Earnings	
Balance at the beginning of the period	11.98	(425.25)	(413.27)
Changes in accounting policy or prior period errors	-	-	-
Restated balance at the beginning of the current reporting period	-	-	-
Profit / (loss) for the year	-	(46.06)	(46.06)
Balance at the end of the period	11.98	(471.31)	(459.33)

31st March, 2025

Particulars	Reserves & Surplus		Total
	Capital Reserve	Retained Earnings	
Balance at the beginning of the period	11.98	(425.22)	(413.25)
Changes in accounting policy or prior period errors	-	-	-
Restated balance at the beginning of the previous reporting period	-	-	-
Profit / (loss) for the year	-	(0.03)	(0.03)
Balance at the end of the period	11.98	(425.25)	(413.27)

For SHAH VALERA & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.: W100238

Priten B. Shah
(Partner)

Membership No. : 149028

Place: Mumbai

Date: 20/05/2026

For and on behalf of the Board of Directors of

June Industries Limited

(Formerly Known as Kashyap Tele-Medicines Limited)

Mr. Kalpesh Sheth
Managing Director
(DIN: 00405151)

Mrs. Heena K. Sheth
Director
(DIN: 07627681)

CS Varsha Sawant
Company Secretary
(Membership No. A72926)

(Mr. Anirudh Shah)
CFO

June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

1 Corporate information

The financial statements are of JUNE INDUSTRIES LIMITED (formerly known as Kashyap Tele-Medicines Limited) ('the Company') for the year ended March 31, 2026. The Company was incorporated on 20th February, 1995. The Company is a public company domiciled in India and is incorporated under the provisions of the Companies Act, 1956 and is listed on Bombay Stock Exchange (BSE). The Company is engaged in trading of pharmaceuticals hygiene and cleanroom products.

The registered office of the Company is located at Unit No. 22 & 23, Hasti Industrial Premises Co-Op Soc Ltd, Plot No R-798, Mahape, MIDC, Navi Mumbai, Ghansoli, Thane, Rabale, Maharashtra, India, 400701.

The financial statements were authorized for issue in accordance with a resolution of the directors on May 20, 2026.

2 Basis of preparation

The financial statements of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) and presentation requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS compliant Schedule III).

The financial statements have been prepared on the historical cost basis.

The financial statements are presented in Indian rupees (INR) and all values are presented in Lakhs, except otherwise indicated.

3 Summary of material accounting policies

3.1 Current vs Non Current Classification

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is current when it is:

- i) Expected to be realised or intended to be sold or consumed in normal operating cycle
- ii) Held primarily for the purpose of trading
- iii) Expected to be realised within twelve months after the reporting period, or
- iv) Cash or cash equivalents unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when it is:

- i) Expected to be settled in normal operating cycle
- ii) Held primarily for the purpose of trading
- iii) Due to be settled within twelve months after the reporting period, or
- iv) There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

All other liabilities are treated as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

3.2 Revenue recognition

Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

The Company considers whether there are other promises in the contract that are separate performance obligations to which a portion of the transaction price needs to be allocated. In determining the transaction price for the sale of goods, the Company considers the effects of variable consideration, the existence of significant financing components, non-cash consideration, and consideration payable to the customer (if any).

Interest income

Interest income is recognised using Effective Interest Rate (EIR) method.

3.3 Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts, if any, as they are considered an integral part of the Company's cash management.



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

3.4 Employees benefits

- Short term employee benefits

Short term benefits comprise of employee costs such as salaries, bonuses, and accumulated absents are accrued in the year in which the associated services are rendered by employees of the Company and are measured at the amounts expected to be paid when the liabilities are settled.

3.5 Earnings per share

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting attributable taxes) by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

3.6 Taxes

The tax expense for the period comprises current and deferred tax. Tax is recognised in the Statement of Profit and Loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

Current income tax

Current tax is measured at the amount expected to be paid to the tax authorities in accordance with the taxation laws prevailing and applicable for the relevant assessment year. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax

Deferred income taxes are recognised for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases in the financial statements. The effect on deferred tax assets and liabilities of a change in the tax rates is recognised using the tax rates and tax laws that have been enacted or substantively enacted by the Balance Sheet date. Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set-off current tax assets against current tax liabilities and the deferred tax assets and deferred tax liabilities relate to the same taxable entity and the same taxation authority.

3.6 Impairment of non-financial assets

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, the recoverable amount of the asset is reviewed in order to determine the extent of impairment loss (if any). Where the asset does not generate cash flows that are independent from other assets, the Company estimates the recoverable amount of the cash generating unit to which the asset belongs.


Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. An impairment loss is recognised in the statement of profit and loss as and when the carrying value of an asset exceeds its recoverable amount.

Where an impairment loss subsequently reverses, the carrying value of the asset (or cash generating unit) is increased to the revised estimate of its recoverable amount so that the increased carrying value does not exceed the carrying value that would have been determined had no impairment loss been recognised for the asset (or cash generating unit) in prior years. A reversal of an impairment loss is recognised in the statement of profit and loss immediately.

3.7 Provisions, contingent liabilities, contingent assets and commitments

A provision is recognised when there is a present legal or constructive obligation as a result of past event; it is probable that an outflow of resources will be required to settle the obligation, and in respect of which a reliable estimate can be made. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates. A disclosure for a contingent liability is made where there is a possible obligation arising out of past event, the existence of which will be confirmed only by the occurrence or non occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation arising out of past event where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

3.8 Fair value disclosures for financial assets and financial liabilities

The management believes that the fair values of non-current financial assets (e.g. Investments and other financial assets), current financial assets (e.g. cash equivalents, trade and other receivables, loans), non-current financial liabilities and current financial liabilities (e.g. Trade payables and other financial liabilities) approximate their carrying amounts.

3.9 Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Financial assets

Initial recognition and measurement

All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in following categories:

A) Equity instruments

All equity instruments are subsequently measured at fair value in the balance sheet, with value changes recognised in statement of profit and loss, except for those equity instruments for which the Company has elected to present value changes in "other comprehensive income". If an equity instrument is not held for trading, the Company may make an irrevocable election for its investments which are classified as equity instruments to present the subsequent changes in fair value in other comprehensive income. The Company makes such election on an instrument by instrument basis.

If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to P&L, even on sale of investment. However, the Company may transfer the cumulative gain or loss within equity.

The Company has elected to present all equity instruments, other than those in subsidiary, through FVTPL and all subsequent changes are recognized in Statement of Profit and Loss.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e. removed from the Company's balance sheet) when:

- > The rights to receive cash flows from the asset have expired, or
- > The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.


Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Impairment of financial assets

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss on financial assets which are measured at amortised cost or Fair value through other comprehensive income (FVOCI).

The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivables.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL.

Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e., all cash shortfalls), discounted at the original EIR. ECL impairment loss allowance (or reversal) recognized during the period is recognized as income/ expense in the statement of profit and loss (P&L). This amount is reflected in a separate line in the P&L as an impairment gain or loss.

For financial assets measured as at amortised cost, ECL is presented as an allowance, i.e. as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write-off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

Financial liabilities

Initial recognition and measurement

All financial liabilities are initially recognised at fair value. The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdraft and derivative financial instruments.

Subsequent measurement

Subsequent measurement of financial liabilities depends on their classification as fair value through Profit and loss or at amortized cost.

All changes in fair value of financial liabilities classified as FVTPL is recognized in the Statement of Profit and Loss. Amortised cost category is applicable to loans and borrowings, trade and other payables. After initial recognition the financial liabilities are measured at amortised cost using the EIR method. Gains and losses are recognized in profit and loss when the liabilities are derecognized as well as through the EIR amortization process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or cost that are integral part of the EIR. The EIR amortization is included as finance cost in the Statement of Profit and Loss.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

Reclassification of financial instruments

After initial recognition, no reclassification is made for financial assets which are equity instruments. For financial assets, which are debt instruments, a reclassification is made only if there is a change in the business model for managing those assets. Changes to the business model are expected to be infrequent. If the Company reclassifies the financial assets, it applies the reclassification prospectively from the reclassification date which is the first day of the immediately next reporting period following the change in the business model.

Offsetting financial assets and financial liabilities

Financial assets and liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

4 Changes in accounting policies and disclosures



New and amended standards

The Ministry of Corporate Affairs has notified Companies (Indian Accounting Standards) Amendment Rules, 2023 dated March 31, 2023 to amend certain Ind AS which are effective for annual periods beginning on or after April 1, 2023. The Company applied for the first-time these amendments and following is the impact that such amendments had an impact on the Company's financial position, performance and/or disclosures:

Disclosure of Accounting Policies - Amendments to Ind AS 1

The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their 'significant' accounting policies with a requirement to disclose their 'material' accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures.

The amendments have had an impact on the Company's disclosures of accounting policies, but not on the measurement, recognition or presentation of any items in the Company's financial statements.



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

5 Significant accounting estimates and assumptions

The preparation of the Company's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Estimates and assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.


Impairment of non-financial assets

Taxes

Deferred tax assets are recognised for unused tax credits to the extent that it is probable that taxable profit will be available against which the credits can be utilised. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques including the DCF model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgment is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments.



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

Particulars	Amount (Rs.) in Lakhs	
	As at	As at
	31st March, 2026	31st March, 2025
6 Other financial assets		
Telephone deposit (measured at amortised cost)	0.34	0.34
	0.34	0.34
7 Other non-current assets		
Advance for software development	-	65.43
	-	65.43

Particulars	Amount (Rs.) in Lakhs	
	As at	As at
	31st March, 2026	31st March, 2025
8 Cash and cash equivalents		
Balances with banks:		
Balance in current account	24.71	0.05
Cash on hand	0.32	0.32
	25.04	0.37
9 Investment		
Fixed Deposit	35.72	-
	35.72	-
10 Current Tax Assets (Net)		
Advance tax paid (net of provision for tax)	0.63	0.16
	0.63	0.16

Particulars	Amount (Rs.) in Lakhs	
	As at	As at
	31st March, 2026	31st March, 2025
11 Share capital		
Authorised Share Capital		
15,00,00,000 (previous year: 15,00,00,000) Equity Shares of INR 1 each	1,500.00	1,500.00
Issued Share Capital		
5,00,00,000 (previous year: 5,00,00,000) Equity Shares of INR 1 each	500.00	500.00
Subscribed and Paid up Share Capital		
4,77,22,000 (previous year: 4,77,22,000) Equity Shares of INR 1 each	477.22	477.22
Total	477.22	477.22

Notes:

(a) Reconciliation of the number of the shares outstanding as at the beginning and end of the year:

Particulars	31st March, 2026		31st March, 2025	
	No. of shares	Amount (Rs.) in Lakhs	No. of shares	Amount (Rs.) in Lakhs
At the beginning of the year	4,77,22,000	477.22	4,77,22,000	477.22
Movement during the year	-	-	-	-
At the end of the year	4,77,22,000	477.22	4,77,22,000	477.22

(b) Terms/rights attached to equity shares:

The Company has only one class of equity shares having a par value of ₹1 per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all liabilities. The distribution will be in proportion to the number of equity shares held by the shareholders.

The Company did not declare any dividend on equity shares for the period ended March 31, 2026 and year ended March 31, 2025. The dividend if proposed by the Board of Directors, is subject to the approval of shareholders in the Annual General Meeting, except interim dividend.

(c) Details of shareholder holding more than 5% shares in the Company

Equity shares of ₹1 each fully paid		As at March 31, 2026	As at Dec 31, 2025	As at Sept 30, 2025	As at June 30, 2025	As at March 31, 2025
June Enterprises Pvt Ltd	Number of Shares	2,90,54,018	2,90,54,018	2,90,54,018	1,49,15,000	1,49,15,000
	% Holding	60.88%	60.88%	60.88%	31.25%	31.25%


(d) Shares reserved for issue under option

The Company has not reserved any shares for issuance under options.

(e) Aggregate number of bonus shares issued, share issued for consideration other than cash and shares bought back during the period of five years immediately preceding the reporting date.

The Company has neither issued any bonus shares, shares for consideration other than cash nor has there been any buyback of shares in the current year and preceding five years.

[Handwritten signature]



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

(f) Details of Equity shares held by promoters:
31st March, 2026

Name of the promoter	No of shares at the beginning of the year	Change during the year	No of shares at the end of the year	% of Total Shares	% Change during the year
Sarbatidevi Agrawal	5,00,000	-	5,00,000	1.05%	-
June Enterprises Private Limited	-	2,90,54,018	2,90,54,018	60.88%	60.88%
Total	5,00,000	2,90,54,018	2,95,54,018	61.93%	-

31st March, 2025

Name of the promoter	No of shares at the beginning of the year	Change during the year	No of shares at the end of the year	% of Total Shares	% Change during the year
Jitendra Tarachand Agrawal	7,49,900	-	7,49,900	1.57%	-
Amit Yamunadutt Agarwal	5,00,000	-	5,00,000	1.05%	-
Sarbatidevi Agrawal	5,00,000	-	5,00,000	1.05%	-
Radheshyam Tarachand Agrawal	3,57,000	-	3,57,000	0.75%	-
Yamunadutt Amilal Agrawal	3,51,000	-	3,51,000	0.74%	-
Jindal Worldwide Limited	1,49,15,000	-	1,49,15,000	31.25%	-
Total	1,73,72,900	-	1,73,72,900	36.41%	-

Particulars	Amount (Rs.) in Lakhs	
	As at 31st March, 2026	As at 31st March, 2025
12 Other equity		
(i) Retained earnings		
Opening balance	(425.25)	(425.22)
Add: Profits / (loss) for the year	(46.06132)	(0.02862)
Closing balance	(471.31)	(425.25)
(ii) Securities Premium		
Total	-	-
(ii) Capital Reserve		
Total	11.98	11.98
	(459.34)	(413.27)

Retained Earnings - Retained Earnings are the profits / (loss) that the Company has earned till date, less any payment of dividend.
Capital Reserve - It represents gain of capital nature which mainly includes gain on reissue of forfeited shares.


Particulars	As at 31st March, 2026	As at 31st March, 2025
13 Other financial liabilities		
Payable for expenses	43.85	2.35
	43.85	2.35

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
14 Revenue from operations		
Income from projects and services	19.70	3.60
Software sales	-	15.60
	19.70	19.20
Timing of revenue recognition		
Services transferred over time	19.70	19.20
Total revenue from contracts with customers	19.70	19.20

Performance obligation


Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
15 Other income		
Interest on IT Refund	-	0.00
other income	1.08	-
Interest On Fixed Deposit	0.80	-
	1.88	0.00



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

		Amount (Rs.) in Lakhs	
		For the year ended March 31, 2026	For the year ended March 31, 2025
16	Employee benefits expense		
	Salaries, wages and allowance	1.91	10.81
		1.91	10.81
17	Other expenses		
	Lease Rent	-	0.60
	Bank charges	0.01	0.00
	Listing expenses	3.84	3.84
	Professional fees	53.59	1.77
	Sundry balances written off	-	0.00
	Issuer fees	0.92	0.77
	Filing fees	3.62	0.06
	Payment to auditor *	1.05	0.35
	Telephone Exp.	-	0.05
	Printing & stationary	-	0.17
	Office Expenses	0.02	-
	Advertisement & Publications	1.37	0.70
	SEBI Fees and Penalty \$	0.78	-
	Travelling Expenses	0.13	-
	Misc Expenses	0.41	0.09
		65.74	8.40
	* Payment to auditor		
	As auditor:		
	Audit fee	1.05	0.35
		1.05	0.35
18	Income Tax		
		For the year ended March 31, 2026	For the year ended March 31, 2025
(a)	Income tax recognised in statement of profit and loss:		
	Current income tax	-	-
	Tax relating to previous year	-	0.02
	Income tax expenses reported in statement of profit and loss	-	0.02
(b)	Income tax recognised in other comprehensive income		
	Net gain/(loss) on re-measurement of defined benefit plans	-	-
		-	-
The income tax expense can be reconciled to the accounting profit as follows:			
	Accounting profit before tax	(46.06)	(0.01)
	Income tax rate as per Income Tax Act 1961 (2025 = 25.17% and 2022 = 25.17%)	-	-
	Adjustments:		
	Expense not deductible expenses for tax purposes	0.20	-
	Deferred tax asset not recognised on losses	(0.20)	-
	Tax relating to Previous Year	-	0.02
	Income tax reported in statement of profit and loss	-	0.02
The Company has elected to exercise the option of a lower tax rate provided under Section 115BAA of the Income-tax Act, 1961, as introduced by the Taxation Laws (Amendment) Ordinance, 2019 dated September 20, 2019. Accordingly, the Company recognises provision for income tax basis the rate provided in the said section.			
19	Earnings per share (EPS)		
	Basic EPS amounts are calculated by dividing the profit for the year attributable on equity holders of the company by the weighted average number of equity shares outstanding during the year.		
	The following reflects the income and share data used in the basic & diluted EPS computation		
	Basic and diluted earning per share		
		For the year ended March 31, 2026	For the year ended March 31, 2025
	Profit attributable to equity shareholders of the Company for basic & diluted earning	(46.06)	(0.03)
	Weighted average number of equity shares for basic & diluted EPS	4,77,22,000	4,77,22,000
	Basic and diluted earning per share (in INR)	(0.097)	(0.000)



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

20 Capital management

- (a) The Company's capital management objectives are to ensure Company's ability to continue as a going concern as well to create value for shareholders by facilitating the meeting of long term and short term goals of the Company. The Company determines the amount of capital required on the basis of annual business plan coupled with long term and short term strategic investment and expansion plans. The funding needs are met through cash generated from operations. The Company monitors the capital structure on the basis of net debt to equity ratio and maturity profile of the overall debt portfolio of the Company. The table below summarises the capital, net debt and net debt to equity ratio of the company:

Particulars	Amount (Rs.) in Lakhs	
	As at March 31, 2026	As at March 31, 2025
Equity share capital	477.22	477.22
Other equity	(459.34)	(413.27)
Total equity	17.88	63.95
Gross Debt	-	-
Gross debt as above	-	-
Less: Cash and cash equivalents	25.04	0.37
Net debt	(25.04)	(0.37)
Net debt to equity	(1.40)	(0.01)


21 Fair value measurement

- (a) The carrying value and fair value of financial instruments by categories as of March 31, 2026 is as follows:

Particulars	Amount (Rs.) in Lakhs		
	Fair value through other comprehensive income	Fair value through other profit & loss	Amortised Cost
Financial assets			
Investments	-	-	35.72
Cash and cash equivalents	-	-	25.04
Others financial assets	-	-	0.34
	-	-	61.09
Financial liabilities			
Other financial liabilities	-	-	43.85
	-	-	43.85

- (b) The carrying value and fair value of financial instruments by categories as of March 31, 2025 is as follows:

Particulars	Amount (Rs.) in Lakhs		
	Fair value through other comprehensive income	Fair value through other profit & loss	Amortised Cost
Financial assets			
Cash and cash equivalents	-	-	0.37
Others financial assets	-	-	0.34
	-	-	0.71



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

Financial liabilities

Other financial liabilities	-	-	2.35
	-	-	2.35

The carrying amounts of trade receivables, cash & cash equivalents and other financial liabilities are considered to be the same as fair value, due to them being short term in nature.

22 Financial instruments risk management objectives and policies

The Company is exposed to various risks in relation to financial instruments. The main types of risks are credit risk and liquidity risk.

(a) Credit Risk

Credit Risk in case of the Company arises from cash and cash equivalents, deposits with banks, as well as credit exposures to customers. including

Credit Risk Management

Credit risk is the risk that a counterparty fails to discharge an obligation to the Company. The Company is exposed to this risk for various financial instruments, for example by granting loans and receivables to customers, placing deposits etc. the Company's maximum exposure to credit risk is limited to the carrying amount of financial assets recognised at March 31, 2026, as summarised below:

	Amount (Rs.) in Lakhs	
	As at March 31, 2026	As at March 31, 2025
Other financial assets	0.34	0.34
Balances with bank	24.71	0.05
	25.05	0.39

The Company continuously monitors defaults of customers and other counterparties and incorporates this information into its credit risk controls. The Company's policy is to deal only with creditworthy counterparties only.

(b) Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due.



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

23 Related Party Disclosures

In accordance with the requirements of Ind AS 24, related party disclosures are as follows:

a) List of related parties

Relationship	Name of related party
Key Management Personnel (KMP)	Mr. Kalpesh Sheth (Managing Director) appointed on 23/05/2025
	Mr. Anirudh Shah (CFO) appointed on 21/07/2025
	CS Varsha Sawant (Whole-time Company Secretary) appointed on 21/07/2025
	CS Jyoti Sahu (Company Secretary) appointment Date - 27/02/2024 & resignation date - 06/04/2025
	Mr. Raghav Agarwal (CFO) resignation date - 23/05/2025
Holding Company	June Enterprises Private Limited
Entities where significant influence is exercised by KMP having transactions with the Company (up to 31st March, 2025)	Amitara Green Hi-tech Park Private Limited
	Amitara Industries Private Limited
	Bhagyalakshmi Spintex Private Limited
	Deepshikha Exim Private Limited
	Expede-tech Research & Development Private Limited
	Gayatri Weavers Private Limited
	Goodcore Spintex Private Limited
	Jindal Creations Private Limited
	Jindal Speciality Chemicals India Private Limited
	JINDAL Mobilitric Private Limited
	Jindal Worldwide Limited
	Kshipan Estates & Enterprise Private Limited
	Madhulika Estate Enterprise Private Limited
	Niharika Threads Private Limited
	Tarachand Impex Private Limited
	Yash Weavers Private Limited

b) Summary of related party transactions

S.No	Particulars	Amount (Rs.) in Lakhs					
		Key Managerial Personnel		Holding Company		Entities where significant influence is exercised by KMP	
		31st March, 2026	31st March, 2025	31st March, 2026	31st March, 2025	31st March, 2026	31st March, 2025
i	Transactions during the year						
	Sale of software						
	Amitara Green Hi-tech Park Private Limited	-	-	-	-	-	0.60
	Amitara Industries Private Limited	-	-	-	-	-	0.60
	Bhagyalakshmi Spintex Private Limited	-	-	-	-	-	0.60
	Deepshikha Exim Private Limited	-	-	-	-	-	0.60
	Expede-tech Research & Development Private Limited	-	-	-	-	-	0.60
	Gayatri Weavers Private Limited	-	-	-	-	-	0.60
	Goodcore Spintex Private Limited	-	-	-	-	-	0.60
	Jindal Creations Private Limited	-	-	-	-	-	0.60
	Jindal Speciality Chemicals India Private Limited	-	-	-	-	-	0.60
	JINDAL Mobilitric Private Limited	-	-	-	-	-	0.60
	Jindal Worldwide Limited	-	-	-	-	-	3.40
	Kshipan Estates & Enterprise Private Limited	-	-	-	-	-	0.60
	Madhulika Estate Enterprise Private Limited	-	-	-	-	-	0.60
	Niharika Threads Private Limited	-	-	-	-	-	0.60
	Tarachand Impex Private Limited	-	-	-	-	-	0.60
	Yash Weavers Private Limited	-	-	-	-	-	0.60
iv	Salaries and other benefits						
	Anirudh Shah	2.25	-	-	-	-	-
	Jyoti Shahu	0.11	7.91	-	-	-	-
	Varsha Sawant	1.80	-	-	-	-	-
	Raghav Agrawal	-	1.20	-	-	-	-
	Rent Paid						
	Amit Agrawal	-	0.60	-	-	-	-

Terms and Conditions of Transactions with Related Parties

The transactions with related parties are made on terms equivalent to those that prevail in arm's length transactions. There have been no guarantees provided or received for any related party receivables or payables.

Compensation of Key Managerial Personnel of the Company

Short-Term Employee Benefits

Post-Employment Benefit Plans

Total Compensation paid to Key Managerial Personnel

Amount (Rs.) in Lakhs	
31st March, 2026	31st March, 2025
4.16	-
-	-
4.16	-



June Industries Limited
(Formerly known as Kashyap Tele-Medicines Limited)
Notes to financial statements for the year ended March 31, 2026
CIN: L46497MH1995PLC085738

24 Segment information

a Basis for Segmentation

The Company's senior management consisting of Managing Director, Directors and Chief Financial Officer, examines the company's performance on the basis of single segment namely Software Sales. Hence, the Company has only one operating segment under Ind AS 108 'Operating Segments' i.e. Software Sales.

b Geographical Information

All the operations and customers of the Company are based in India only. Hence all the revenue is generated from India and all the assets of the Company are located in India.

c Major customer - Following are the details of revenue generated from single customer which has accounted for more than 10% of the Company's revenue:

25 Ratio Analysis and its elements

Ratio	Numerator	Denominator	31st March, 2026	31st March, 2025	% change *
Current Ratio	Current Assets	Current Liabilities	1.40	0.22	5.22
Debt- Equity Ratio	Total Debt	Shareholder's Equity	This ratio is not applicable to the Company as there is no debt raised by the Company		
Debt Service Coverage ratio	Earnings for debt service	Debt service	This ratio is not applicable to the Company as there is no debt raised by the Company		
Return on Equity ratio	Net Profits after taxes	Shareholder's Equity	(2.58)	(0.00)	>100%
Inventory Turnover ratio	Cost of goods sold	Average Inventory	This ratio is not applicable to the Company as the Company does not hold inventory		
Trade Receivable Turnover Ratio	Net credit sales = Gross credit sales - sales return	Average Trade Receivable	This ratio is not relevant as there are no major customer balances outstanding in current year and previous year.		
Trade Payable Turnover Ratio	Net credit purchases	Average Trade Payables	This ratio is not applicable to the Company does not have any trade payables		
Net Capital Turnover Ratio	Net sales = Total sales - sales return	Working capital = Current assets - Current liabilities	1.12	(10.53)	(>100%)
Net Profit ratio	Net Profit	Net sales = Total sales - sales return	-2.34	(0.00)	(>100%)
Return on Capital Employed	Earnings before interest and taxes	Capital Employed = Tangible Net Worth + Total Debt + Deferred Tax Liability	(2.58)	(0.00)	>100%
Return on Investment	Interest (Finance Income)	Investment	0.02	0.00	(>100%)

The major reason for variation in Current Ratio and Net Capital Turnover Ratio is mainly due to increased payables for expenses.

The major reason for improvement in profitability and margin related ratios is mainly due to the reason that the profit / (loss) for the current year is impacted due to penalty charged by BSE Limited and increased employee benefit expenses.

* The numbers in brackets represent that the numbers are in negative.

26 Other Statutory Information

(i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(ii) The Company does not have any transactions with companies struck off.

(iii) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

(iv) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

(v) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

(vi) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,

(vii) The Company does not have any transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

(viii) Other Additional Regulatory information as per Schedule III are not applicable to the company.


27 Previous year figures have been re-grouped wherever necessary.

For SHAH VALERA & ASSOCIATES LLP

Chartered Accountants

Firm Registration No.: W100238


Priten B. Shah
(Partner)
Membership No. : 149028



For and on behalf of the Board of Directors of
June Industries Limited
(Formerly Known as Kashyap Tele-Medicines Limited)


Mr. Kalpesh Sheth
Managing Director
(DIN: 00405151)


Mrs. Heena K. Sheth
Director
(DIN: 07627681)


CS Varsha Sawant
Company Secretary
(Membership No. A72926)


Mr. Anirudh Shah
CFO

Place: Mumbai
Date: 20/05/2026